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Abstract
My thesis work focuses on developing reliable and innovative statistical
methods for improving analyses of biomedical data. I address two types of
questions: improving precision of randomized clinical trials and identifying
brain networks using brain imaging. For randomized clinical trials, we proved
the statistical validity of two commonly used methods to improve precision
while being robust to misspecification of models used in the analysis. We
demonstrated our results by re-analyzing completed randomized trials and
showed that substantial precision gain can be achieved by these two meth-
ods. For brain imaging, we proposed a consistent estimator for the brain net-
works that are common across people. Applied to a motor-task functional mag-
netic resonance imaging data set, our estimator identifies meaningful brain
networks that are consistent with current scientific understandings of motor
networks.
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My thesis research lies in two areas: (1) causal inference for clinical trials
and (2) statistical modeling for brain imaging. In causal inference for clinical
trials, the open question I address is how to perform model-robust inference,
i.e. valid inference without requiring a correct model, and how to improve pre-
cision when estimating a treatment effect. In the analysis of brain imaging
data, I study the identification of brain networks that are common among peo-
ple. These two areas of my research differ substantially. However, a common
component of my research is that the proposed statistical methods improve the
existing methods both empirically (via simulation and real data analysis) and
theoretically (by asymptotic results, i.e., consistency and asymptotic variance).
In addition, both areas have connections to what is classically called “adjust-
ment”. In the randomized trial setting, we seek robust and theoretically valid
1
CHAPTER 1. INTRODUCTION
forms of adjustment. In brain imaging we exploit parsimony.
Chapter 2 focuses on ANCOVA in randomized clinical trials. ANCOVA in-
volves fitting a linear regression model for the primary outcome on intercept,
treatment allocation and baseline variables. The estimated regression coeffi-
cient of the treatment allocation term is the ANCOVA estimator of the average
treatment effect (Yang and Tsiatis, 2001). According to two surveys (Pocock
et al., 2002; Austin et al., 2010), there is confusion regarding the statistical va-
lidity of ANCOVA when the linear model is misspecified. This is an important
question, because model misspecification is almost unavoidable in practice. We
clarify this issue by proving that the ANCOVA estimator is robust to arbitrary
model misspecification and explain how ANCOVA can reduce variance. Our
results apply to analyses of phase 2 or 3 trials and can help reduce the re-
quired sample size to achieve a desired power. Applied to randomized trials
for mild cognitive impairment, schizophrenia, and depression, we demonstrate
that ANCOVA brings a 4% to 32% precision gain.
Chapter 3 concerns stratified randomization and covariate adjustment, which
are two commonly used methods for improving precision and power in clinical
trials. Stratified randomization refers to a randomization procedure that, by
design, attempts to create balance across study arms in strata of baseline vari-
ables. Covariate adjustment means adjusting for baseline variables in estima-
tion at the end of the trial (or at interim analyses). According to a survey by
2
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Kahan and Morris (2012), many trials do not fully capture the combined preci-
sion gain from these two methods, which may lead to increased sample size or
prolonged trial duration. We derive consistency and asymptotic normality for
a large class of estimators that involves stratified randomization and covariate
adjustment. We show that these two methods can lead to substantial gains
in precision and power by re-analyzing three trials of substance use disorder
treatments, where the variance reduction due to stratified randomization and
covariate adjustment ranges from 1% to 36%. Our results are most useful in
improving precision of phase 2 or 3 trials and can handle a variety of outcome
types, repeated measures outcomes and missing outcome data.
Chapter 4 considers a problem of jointly modeling multiple covariance ma-
trices, assuming a proportion of eigenvectors to be shared across while the
rest are individual-specific. This problem is motivated by functional magnetic
resonance imaging (fMRI) data, where correlations among brain regions form
covariance matrices, and our goal is to identify common brain networks (i.e.
shared eigenvectors), which represent correlations in functional brain mea-
sures consistent across subjects. We solve this problem by proposing consistent
estimators of the shared eigenvectors and the number of the shared eigenvec-
tors. In a data set of motor-task fMRI, our estimator identifies meaningful
brain networks that are consistent with current scientific understandings of
motor networks during a motor paradigm. In general, our proposed estimator
3
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can help better understand brain functions and is also applicable to similar
questions in other areas, such as genomics and economics.




(ANCOVA) in Randomized Trials:
More Precision and Valid
Confidence Intervals, Without
Model Assumptions
The content of this chapter is reproduced from Wang et al. (2019) available
at https://doi.org/10.1111/biom.13062.
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CHAPTER 2. ANCOVA ROBUSTNESS AND PRECISION GAIN IN
RANDOMIZED TRIALS
2.1 Introduction
Pocock et al. (2002), in a survey of 50 randomized trial reports, found that 36
used covariate adjustment, but only 12 emphasized adjusted over unadjusted
estimators. They stated that “the statistical properties of covariate-adjustment
are quite complex and often poorly understood, and there remains confusion as
to what is an appropriate statistical strategy.” Austin et al. (2010), in a paper
titled “A substantial and confusing variation exists in handling of baseline co-
variates in randomized controlled trials: a review of trials published in leading
medical journals”, surveyed 114 randomized trial articles and found that only
39 of them presented an adjusted analysis.
We focus on the analysis of covariance (ANCOVA) estimator, referred to as
“ANCOVA I” by Yang and Tsiatis (2001). It involves fitting a linear regression
model for the primary outcome with intercept and main terms for the treat-
ment assignment and baseline variables. For trials with continuous-valued
or change score outcomes, covariate adjustment often involves the ANCOVA
estimator. We use the term “covariate adjustment” to refer to the ANCOVA
estimator.
Concerns have been raised about the validity of ANCOVA for analyzing ran-
domized trial data when the linear model is misspecified. For example, Krae-
mer (2015) states “The linear model used for covariate adjusting (e.g., analysis
6
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of covariance) assumes ... that there is no interaction between the covariates
and the treatment effect.” and “Given these risks for bias, ANCOVA should
not generally be used for such adjustment.” Ludvigsson et al. (2008) and Mon-
talban et al. (2017) both checked whether data is normally distributed before
applying ANCOVA and Ludvigsson et al. (2008) state that “ANCOVA involves
the assumption of normally distributed response data and homogeneity of vari-
ances.” These authors are wise to have the general concern about model mis-
specification, since in many contexts it can lead to biased or uninterpretable
analyses. However, when the ANCOVA estimator is used to analyze random-
ized trial data, it has special robustness properties that obviate the above con-
cerns.
Yang and Tsiatis (2001) proved that the ANCOVA estimator is consistent
under arbitrary misspecification of the linear model. We build on this result by
proving that the standard error, computed as if the linear model were correct,
is also consistent. Therefore, not only estimates but also confidence intervals
and hypothesis tests conducted as if the linear model were correct are asymp-
totically valid even when the linear model is arbitrarily misspecified, e.g., when
the true relationships between variables are non-linear, and/or when there is
treatment effect heterogeneity. This is important since it is not possible to rule
out all types of model misspecification.
We attempt to provide intuition behind the precision gains from covariate
7
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adjustment by showing a direct analogy to ordinary least squares linear re-
gression. We prove that the asymptotic variance reduction (i.e., precision gain)
due to covariate adjustment equals the fraction of variance in the primary out-
come explained by the baseline variables, beyond what is already explained by
the main effect of treatment. This holds under arbitrary model misspecifica-
tion and leads to a simple formula for estimating the variance reduction due to
ANCOVA. This variance reduction is important since it equals the reduction in
the required sample size to achieve a desired power.
The above results build on key ideas from Tsiatis et al. (2008); Rubin and
van der Laan (2008); Moore and van der Laan (2009a); Moore et al. (2011);
Rubin and van der Laan (2011); Jiang et al. (2018); Tian et al. (2019). As in
their work, our results are asymptotic, i.e., they hold in the limit as sample size
grows to infinity while the set of covariates is fixed. A special case of the results
of Bugni et al. (2018) coincides with a special case of our result in Section 4.2
(explained in that section).
We present data analyses based on three completed randomized clinical tri-
als for treatment of mild cognitive impairment (MCI) (Petersen et al., 2005),
schizophrenia (Jarskog et al., 2013), and depression (Treatment for Adoles-
cents With Depression Study (TADS) Team, 2004), respectively. By analyzing
these data sets, we demonstrate how covariate adjustment can reduce vari-
ance, have greater added value in large trials in terms of reducing the re-
8
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quired sample size to achieve a desired power, and increase power even when
by chance there is perfect or near-perfect balance across arms in the baseline
variables (due to the ANCOVA estimator’s smaller standard error).
In the next section, we describe the three trials. In Section 2.3, we define
the unadjusted estimator, ANCOVA estimator, and covariate imbalance. In
Section 2.4, we present our main results. Illustrations are provided in Sec-
tion 2.5, where trial analyses are presented. Some practical recommendations
for applying covariate adjustment are given in Section 2.6.
2.2 Three Completed Randomized Clin-
ical Trials
2.2.1 Mild Cognitive Impairment (MCI) Trial
The “Vitamin E and Donepezil for the Treatment of Mild Cognitive Impair-
ment” (MCI) phase 3 randomized trial was completed in 2004 (Petersen et al.,
2005). The goal was to estimate the effect of a drug treatment on preventing
progression from MCI to Alzheimer’s disease. Participants were randomized to
three arms: the drug Donepezil, Vitamin E, and placebo control. We compare
the Donepezil arm (253 participants, 33% missing outcomes) to the placebo
arm (259 participants, 28% missing outcomes). The primary outcome was time
9
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to progression to Alzheimer’s disease. In order to apply the ANCOVA estima-
tor, which requires a continuous or change score outcome, we instead use the
change in Clinical Dementia Rating-sums of boxes score (CDR-SB) between
baseline and 18 months. We use the following baseline variables for adjust-
ment: age, gender, Alzheimer’s Disease Assessment Scale (ADAS)-cognitive
score, Mini–Mental State Examination (MMSE) score, Activities of Daily Liv-
ing total score, Global Deterioration scale, and CDR-SB.
2.2.2 Metformin for Weight Loss (METS) Trial
The “Metformin for weight loss and metabolic control in overweight out-
patients with schizophrenia and schizoaffective disorder” trial, referred to as
“METS”, is a phase 4 randomized trial completed in 2010 (Jarskog et al., 2013).
Participants were randomly assigned to two arms: Metformin (treatment, 75
participants, 15% missing outcomes) and placebo (control, 71 participants, 14%
missing outcomes). The primary outcome was weight loss over 16 weeks. We
use this outcome and the following baseline variables: age, gender, Clinical
Global Impressions (CGI) severity rating score, tobacco use, illicit drug use,
alcohol use, weight and body mass index (BMI).
10
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2.2.3 Treatment for Adolescents with Depression
Study (TADS)
The “Treatment for Adolescents with Depression Study” (TADS) is a phase
3, four-arm, randomized trial completed in 2003 (Treatment for Adolescents
With Depression Study (TADS) Team, 2004). The goal was to evaluate cognitive-
behavioral therapy (CBT) and Fluoxetine (FLX), each alone and combined (CMB),
for treating major depressive disorder in adolescents (age 12–17). Participants
were randomized to four arms: FLX only (109 participants, 15% missing out-
comes), CBT only (111 participants, 29% missing outcomes), combined (CMB,
107 participants, 16% missing outcomes), and placebo (112 participants, 20%
missing outcomes). The co-primary outcomes were the change in Children’s
Depression Rating Scale-Revised (CDRS-R) score and improvement of Clinical
Global Impressions (CGI) severity rating score at 12 weeks. We focus on the
former outcome and adjust for the following baseline variables: age, gender,
CDRS-R score, CGI severity rating score, Children’s Global Assessment Scale
score (CGAS), Reynolds Adolescent Depression Scale total score (RADS), sui-
cide ideation score, current major depressive episode duration, and comorbidity
(indicator of any other psychiatric disorder except dysthymia).
11
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2.3 Definitions
2.3.1 Estimators of Average Treatment Effect
We focus on randomized clinical trials where each participant contributes
the generic data vector (W , A, Y ), where W is a k × 1 column vector of prede-
fined baseline variables, A is the study arm assignment, and Y is the outcome.
We assume that Y is continuous or a change score (difference between a score
measured at follow-up and baseline). We assume the study arm assignment
indicator A is binary (A = 1 for treatment and A = 0 for control). For trials
with more than 1 treatment (e.g., TADS), we consider each treatment arm vs.
control comparison separately.
The components of the baseline vectorW can be continuous, binary, ordinal
and/or categorical. All variables are assumed to be bounded. We assume that
the components of (1,W t) are linearly independent, i.e., no component is a lin-
ear combination of the others; otherwise at least one component is redundant
and can be dropped from the corresponding design matrix.
For each participant i = 1, . . . , n, we observe the data vector (Wi, Ai, Yi),
which we assume to be an independent, identically distributed draw from the
unknown, joint distribution on the generic data vector (W , A, Y ). The only as-
sumption that we make about the joint distribution is that the study arm A
is randomly assigned with equal probability to treatment or control indepen-
12
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dent of the baseline variables W . This holds by design in trials using simple
randomization with equal probability of assignment to each study arm, which
is the type of trial design that we consider throughout. The assumptions in
this paragraph do not hold in trials that use stratified block randomization or
covariate-adaptive randomization, which are discussed in Section 2.6.
The goal is to estimate the population average treatment effect ∆ = E[Y |A =
1] − E[Y |A = 0], i.e., the difference between population means if everyone in
the study population had been assigned to treatment versus control. We fo-
cus throughout on estimating the average treatment effect ∆, since that is the
principal quantity of interest in the primary efficacy analysis of randomized
trials (Tsiatis et al., 2008). An estimator of the average treatment effect ∆ is
called robust to arbitrary model misspecification if it is consistent under the
aforementioned assumptions. These assumptions do not put any restrictions
on the joint distribution ofW , A, Y other than A being randomly assigned with
equal probability to each arm independent of the baseline variables W . E.g.,
the baseline variables can be correlated with each other and the treatment
can be more/less effective for different subpopulations defined by the baseline
variables.
Denote the unadjusted estimator (which ignores baseline variables) of the
13
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The unadjusted estimator is consistent, i.e., converges to ∆ as the sample size
goes to infinity.
The ANCOVA estimator of the average treatment effect ∆ adjusts for chance
imbalance between study arms in W . It is computed by fitting the following
linear regression model
E[Y |A,W ] = β0 + βAA+ βtWW , (2.1)
using ordinary least squares (OLS). Denote the estimated coefficients by
β̂0, β̂A, β̂W . The ANCOVA estimator ∆̂ancova of the average treatment effect ∆ is
the estimated coefficient β̂A.
According to Huitema (2011), the ANCOVA model assumes: (i) a linear re-
lationship between the outcome and the other variables, i.e., Y = β0 + βAA +
βtWW + ε, where ε is the error term, and (ii) the distribution of the error ε
is normal with mean 0 conditional on A and W . These assumptions may fail
to hold if there is an interaction between treatment and covariate (Kraemer,
2015), if there are unmeasured prognostic covariates that are correlated with
W (Austin et al., 2010), or if the outcome is non-linearly related to the covari-
14
CHAPTER 2. ANCOVA ROBUSTNESS AND PRECISION GAIN IN
RANDOMIZED TRIALS
ates. Fortuitously, the key statistical properties of ANCOVA (consistency of
the point estimate and standard error) hold under any of these types of model
misspecification.
Yang and Tsiatis (2001) proved that the ANCOVA estimator is consistent
for ∆, i.e., β̂A converges to ∆ in probability, even under arbitrary misspecifica-
tion of the linear model (2.1). Furthermore, the ANCOVA estimator is asymp-
totically normal and we denote its asymptotic variance as V ar∗(∆̂ancova), i.e.,
n1/2(∆̂ancova −∆) converges to a normal distribution with mean 0 and variance
V ar∗(∆̂ancova). Yang and Tsiatis (2001) also proved that when the probability of
being randomized to each study arm is equal (as assumed here), the ANCOVA
estimator has asymptotic variance at most that of the unadjusted estimator; if
any baseline variable is correlated with the outcome, then ANCOVA is strictly
more precise.
We use the ANCOVA estimator ∆̂ancova = β̂A to estimate the average (also
called marginal) treatment effect ∆ = E[Y |A = 1]−E[Y |A = 0], which is not as-
sumed to be constant across strata ofW . We emphasize this to avoid confusion,
since the conventional interpretation of the estimated coefficient β̂A is the con-
ditional treatment effect. That interpretation does not apply when the model
is misspecified. For example, when the treatment effect differs within strata of
W , then the conditional treatment effect is not a single number but instead is
a function mapping each stratum of W to the corresponding effect. Though it
15
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is of independent interest to estimate the conditional treatment effect, this is
often much more challenging and requires more assumptions than estimating
the marginal treatment effect ∆ (since it involves estimating a function rather
than a single number). The reason for considering baseline variables at all
when estimating the marginal treatment effect ∆ is that this can improve pre-
cision and power by accounting for chance imbalances across study arms (Yang
and Tsiatis, 2001).
The imbalance I between study arms in the baseline variables W , called
chance imbalance or covariate imbalance, is the difference between sample





i=1(1 − Ai)Wi /
∑n
i=1(1− Ai). Although A is independent of W by design, in
any realization the baseline variables can be imbalanced.
2.3.2 ANCOVA Variance Decomposition and Def-
inition of R2Y−∆A∼W
We review properties of OLS regression and define a quantity (R2Y−∆A∼W )
that plays a key role in our main results in Section 2.4. All results below hold
under arbitrary model misspecification.
Consider regressing a generic response variable Z on a covariate vector X
using the linear model E[Z|X] = β0 + βtXX. We assume that all variables are
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bounded and the components of (1,X t) are linearly independent. If the model
is misspecified, i.e., if for every possible β0,βX we have E[Z|X] 6= β0 + βtXX,
then the OLS estimator β̂0, β̂X (based on independent, identically distributed
vectors (Xi, Zi) : i = 1, . . . , n) still converges to a limit, denoted β0,βX . The
variance of Z decomposes as V ar(Z) = V ar(β0 + β
t
XX) + V ar(Z − β0 − βtXX),
where β0 + β
t
XX is the predicted response and Z − β0 − βtXX is the residual.
In other words, the response variance is the sum of the prediction variance and
residual variance. The fraction of the variance of Z explained by covariates
X, denoted R2Z∼X , is defined as 1− V ar(Z − β
t
XX)/V ar(Z) (where we omit the
intercept β0 here and below since it does not impact the variance).
We apply the above variance decomposition to the linear regression model
(2.1) that is used in computing the ANCOVA estimator. Let (βA,βW ) denote
the limit in probability of the OLS estimator (β̂A, β̂W ) for the linear model (2.1)
as sample size n goes to infinity. Our interest is in the variance in the out-
come Y explained by baseline variables W , beyond what is already explained
by treatment A. Therefore, we set the response to be Z = Y − βAA and re-
gressor to be X = W . The following variance decomposition, analogous to the
decomposition of V ar(Z) above, is proved in the Supporting Information:
V ar(Y − βAA) = V ar(βtWW ) + V ar(Y − βAA− βtWW ). (2.2)
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The corresponding fraction of the variance in the outcome Y explained by the
baseline variables W , beyond what is already explained by (the main effect of)
treatment A, is denoted by
R2Y−∆A∼W = 1− V ar(Y − βAA− βtWW )/V ar(Y − βAA). (2.3)
The subscript in R2Y−∆A∼W is to indicate that this R-squared represents the
fraction of variance of Y −∆A explained byW , where we made the substitution
βA = ∆ on the right side of (2.3), which holds by the consistency result of Yang
and Tsiatis (2001).
The importance of R2Y−∆A∼W is that, as we show below, it is identical to the
asymptotic variance reduction (equivalently, the sample size reduction) com-
paring the ANCOVA estimator to the unadjusted estimator, and that this holds
under arbitrary misspecification of (2.1). This result builds on fundamental
ideas from Rubin and van der Laan (2008); Moore and van der Laan (2009a) as
described below.
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2.4 R2Y−∆A∼W and the Relationship Among
Unadjusted Estimator, ANCOVA Es-
timator, and Covariate Imbalance,
Under Model Misspecification
All results below hold under arbitrary model misspecification. Our first re-
sult, in Section 2.4.1, is an equivalence between the ordinary least squares
variance decomposition (2.2) and a variance decomposition relating the un-
adjusted estimator, ANCOVA estimator, and covariate imbalance. Second, in
Section 2.4.2, we show that the variance estimator for ANCOVA computed by
standard statistical software is consistent. Our third result, in Section 2.4.3,
is a simple formula for the variance reduction (equivalently, the sample size
reduction) due to covariate adjustment. These results build on ideas from prior
work as described below.
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2.4.1 Connecting OLS Regression to the Rela-
tionship Among Unadjusted Estimator, AN-
COVA Estimator, and Covariate Imbalance
Jiang et al. (2018) proved the following relationship among the unadjusted
estimator ∆̂unadj, ANCOVA estimator ∆̂ancova, and chance imbalance I:
∆̂unadj ≈ βtW I + ∆̂ancova. (2.4)
(Formally, the difference between the left and right sides of the above display,
after multiplying by n1/2, converges to 0 in probability.) They also showed the
following variance decomposition:
V ar∗(∆̂unadj) = V ar∗(βtW I) + V ar
∗(∆̂ancova), (2.5)
where V ar∗ denotes asymptotic (i.e., large sample) variance.
We show that the above variance decomposition among the unadjusted es-
timator, chance imbalance, and ANCOVA estimator is identical to the variance
decomposition (2.2) for OLS, under arbitrary model misspecification. Specifi-
cally, we prove in the Supporting Information that each term in (2.5) equals
4 times the corresponding term in (2.2), i.e., V ar∗(∆̂unadj) = 4V ar(Y − βAA),
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V ar∗(βtW I) = 4V ar(β
t
WW ), and V ar∗(∆̂ancova) = 4V ar(Y − βAA− βtWW ). This
is summarized in Figure 2.1, where the first row is the variance decomposition
in OLS, the second row is the variance decomposition of ∆̂unadj from Jiang et al.
(2018), and our contribution is to connect them by proving equality of quan-
tities in the same column. When model (2.3.1) is misspecified, all equalities
in Figure 2.1 still hold. These relationships are used to prove the results in
Sections 2.4.2 and 2.4.3.
2.4.2 Robustness of the ANCOVA Variance Esti-
mator to Arbitrary Model Misspecification
Consider the ANCOVA model-based variance estimator for ∆̂ancova that is
output by standard statistical software such as ‘summary.lm’ in R or ‘proc reg’
in SAS, which we denote by V̂ ar(∆̂ancova). The formula for V̂ ar(∆̂ancova) is
V̂ ar(∆̂ancova) =
V̂ ar(Y − β̂0 − β̂AA− β̂tWW )
(n− 1)[V̂ ar(A)− Ĉov(W , A)tV̂ ar(W )−1Ĉov(W , A)]
(2.6)
where on the right side V̂ ar, Ĉov are the sample variance and sample covari-
ance, respectively, where degrees of freedom are taken into account. (See the
Supporting Information for precise definitions of these.) The following theorem
shows that the above variance estimator is robust to arbitrary model misspec-
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ification. (See the Supporting Information for proof.)
Theorem 1. Given the assumptions in Section 2.3.1, which do not assume
that the linear model (2.1) is correctly specified, n times the estimated variance
V̂ ar(∆̂ancova) converges in probability to the true asymptotic variance V ar∗(∆̂ancova)
of the ANCOVA estimator ∆̂ancova.
The above theorem implies that confidence intervals and Wald-type hypothe-
sis tests conducted as if the linear model were correct are asymptotically valid
even when the linear model is arbitrarily misspecified. The 1 − α confidence
interval for the coefficient on the A term in (2.1) that is output by the afore-









where tn−p,α/2 is the α/2-quantile of the t-distribution with n − p degrees of
freedom where p is the number of coefficients in the linear model (2.1). For
large n and fixed p, the quantile tn−p,α/2 is approximately the α/2-quantile of
the standard normal distribution. It follows from the above theorem that the
above display is an asymptotically valid confidence interval for the average
treatment effect ∆, under arbitrary model misspecification.
Bugni et al. (2018) focused on trials using covariate-adaptive randomiza-
tion, but their results also have implications for simple randomization as con-
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sidered here. In particular, the special case of the above theorem where W is a
single, categorical variable follows from Theorem 4.3 and Remark 4.6 of Bugni
et al. (2018).
2.4.3 R2Y−∆A∼W Equals Precision Gain (and Sam-
ple Size Reduction) Due to Adjustment, Even
Under Arbitrary Model Misspecification
Borm et al. (2007) and Rubin and van der Laan (2008) connect the R-
squared from regressing Y on W to the variance reduction due to ANCOVA,
while Moore and van der Laan (2009a) and Moore et al. (2011) make a similar
connection in the context of binary outcomes and estimators based on logistic
regression models. Each of the aforementioned approaches requires conditions
(such as the linear model being correctly specified or that ∆ = 0) or requires
additional factors to connect the R-squared to the variance reduction due to co-
variate adjustment. (See the Supporting Information for more details.) Build-
ing on key ideas from their approaches, we prove that the R-squared R2Y−∆A∼W
equals the variance reduction due to ANCOVA without requiring these condi-
tions or extra factors; this R-squared (which differs from the prior work above
by incorporating A) is robust to arbitrary model misspecification.
It follows from the relationships in Figure 2.1 that the fraction R2Y−∆A∼W of
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the variance in the outcome Y explained by the baseline variables W , beyond
what is explained by the treatmentA, equals the asymptotic variance reduction
due to ANCOVA, i.e.,
R2Y−∆A∼W = 1−
V ar(Y − βAA− βW tW )
V ar(Y − βAA)




The first equality is the definition of R2Y−∆A∼W , and the second shows that
R2Y−∆A∼W equals the variance reduction due to ANCOVA (expression on the
right). The rightmost expression, by definition, equals one minus the asymp-
totic relative efficiency (also called Pitman efficiency) comparing the unad-
justed to the ANCOVA estimator.
In practice, R2Y−∆A∼W can be estimated by
R̂2Y−∆A∼W = 1− V̂ ar(∆̂ancova)/V̂ ar(∆̂unadj), where V̂ ar(∆̂ancova) is the variance of
the ANCOVA estimator output by standard statistical software as in (2.6), and
V̂ ar(∆̂unadj) is the variance of the unadjusted estimator estimated analogously
(by regressing Y on A and an intercept).
The variance reduction (2.8) due to ANCOVA is important since it equals
the fractional sample size reduction that can be achieved through covariate
adjustment when holding the desired power fixed, asymptotically. A variance
reduction of p% means that the sample size required to achieve a desired power
is also reduced by p%. Therefore, R̂2Y−∆A∼W can be used to estimate the bene-
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fits of covariate adjustment in terms of sample size reduction. The R̂2Y−∆A∼W
values from our data sets range from 4% to 32%, which can be translated into
4% to 32% sample size reductions.
Figure 2.1: Variance decomposition equivalence between linear regression
and estimators of average treatment effect. The variance decomposition in
the first row is a result of OLS linear regression. The second row gives the
asymptotic variance decomposition of the unadjusted estimator, which is a mi-
nor extension of key results from Jiang et al., 2018; Tian et al., 2019. Our
contribution is to connect the two variance decompositions by showing their
equivalence, i.e., quantities in the same column are equal, under arbitrary
model misspecification.
2.5 Clinical Trial Applications
Our data analyses for each application (MCI, METS, TADS) are summa-
rized in Table 2.1 and described below. All baseline variables were standard-
ized and missing baseline values were imputed by the median for continuous
25
CHAPTER 2. ANCOVA ROBUSTNESS AND PRECISION GAIN IN
RANDOMIZED TRIALS
variables and the mode for binary and categorical variables. All participants
with missing outcomes were removed from the analysis, for simplicity; in prac-
tice, missing outcome data would be handled as described in Section 2.6. Point
estimates and standard errors are rounded to the nearest 0.01. “Confidence
Interval” is abbreviated as “CI”.
Table 2.1: Summary of clinical trial data analyses: unadjusted estimator for
average treatment effect, adjusted estimator (ANCOVA) for average treatment
effect, 95% confidence intervals (CI), and estimated variance reduction due to










MCI -0.19(-0.49, 0.11) -0.18(-0.45, 0.08) 25%
METS -3.66(-6.83, -0.49) -3.60(-6.71, -0.50) 4%
TADS(FLX) -1.44(-6.02, 3.15) -4.36(-8.14, -0.58) 32%
TADS(CBT) 2.22(-1.93, 6.38) 0.50(-3.20, 4.20) 21%
TADS(CMB) -6.64(-10.97, -2.32) -7.65(-11.28, -4.03) 30%
For the MCI trial, the unadjusted treatment effect estimate was ∆̂unadj =
−0.19 CDR-SB points with standard error 0.15 and 95% CI (−0.49, 0.11), and
the ANCOVA estimate was ∆̂ancova = −0.18 CDR-SB points with standard er-
ror 0.13 and 95% CI (−0.45, 0.08). Compared to the unadjusted estimator, the
ANCOVA estimator has a 14% narrower confidence interval and 25% smaller
variance, indicating that researchers planning to perform an adjusted analy-
sis could achieve the same precision as the unadjusted analysis with approxi-
mately 25% fewer participants.
For the METS trial, the unadjusted treatment effect estimate is ∆̂unadj =
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−3.66 kg of weight change with standard error 1.62 and 95% CI (−6.83,−0.49),
and the ANCOVA estimate is ∆̂ancova = −3.60 with standard error 1.58 and 95%
CI (−6.71,−0.50). Adjustment resulted in a 4% variance reduction.
For the TADS trial, as shown in Table 2.1, covariate adjustment results in
substantial variance reduction for all three treatment arms. This stands out
for the Fluoxetine arm, where we estimated that covariate adjustment reduced
asymptotic variance by 32%. The ANCOVA estimator, unlike the unadjusted
estimator, leads to a statistically significant treatment effect −4.36 CDRS-R
points (p-value 0.01); the 95% CI of the ANCOVA estimator (−8.14,−0.58) ex-
cludes zero, but that of the unadjusted estimator (−6.02, 3.15) does not.
2.6 Practical Recommendations
Consider the case where the primary outcome Y is a change score (differ-
ence between final score and baseline score). In some cases, adjusting for the
baseline score alone brings substantial variance reduction. For example, for
TADS(FLX) and TADS(CMB), adjusting for only the baseline CDRS-R score
gives a similar variance reduction as adjusting for all of the baseline covariates.
In other cases, the baseline score can have negligible impact while the other
covariates provide substantial variance reduction. E.g., in the MCI trial the
baseline score provided approximately 0% variance reduction while the other
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covariates led to an estimated 25% variance reduction. It is fine to adjust for
correlated baseline variables as long as each adds some new prognostic infor-
mation for the primary outcome.
When the trial has missing outcomes, under the assumption of missing
at random (that the outcome distribution is the same for those with missing
outcomes as for those with observed outcomes, conditional on treatment as-
signment and baseline covariates), the unadjusted estimator may no longer be
consistent. This can happen if, e.g., participants who benefit more from treat-
ment are more likely to drop out than those who benefit less. The ANCOVA
estimator remains consistent under missing at random if the ANCOVA model
is correctly specified. To add robustness to model misspecification, one can
use a propensity score model for missing outcomes (modeling the probability of
missingness given treatment assignment and covariates with, e.g., a logistic re-
gression model) as the inverse weight when fitting the ANCOVA model among
those with observed outcomes. According to Robins et al. (2007), this estimator
due to Marshall Joffe is doubly-robust, i.e., consistent as long as one of the two
models (propensity score model or ANCOVA model) is correctly specified, under
the missing at random assumption. For the three trial examples in this paper,
the ANCOVA estimator (which does not incorporate information from partici-
pants with missing outcomes) and the aforementioned doubly-robust extension
(which incorporates information from all participants) gave similar estimates
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and confidence intervals. See the Supporting Information for details.
For large trials, e.g., with total sample size at least 500, adjusting for prog-
nostic baseline variables (if there are any) is highly recommended since it re-
duces the required sample size to achieve a desired power (EMA, 2015). This
is counter to the (false) intuition that in large trials there is little to gain from
covariate adjustment since randomization will likely leave little imbalance to
adjust for. Adjustment can still be useful at large sample sizes, and arguably
can be more useful since it leads to greater absolute reductions in the required
sample size. For example, the METS trial involved 146 participants and our
estimate of R2Y−∆A∼W is 4%. If this were the true value of R2Y−∆A∼W , it would
mean about 6 fewer participants required to achieve the same power as the
unadjusted estimator; if this trial were 10 times larger, i.e., 1460 participants,
then covariate adjustment would lead to a sample size reduction of approxi-
mately 60 participants.
Even when a randomized trial ends up having negligible imbalance, covari-
ate adjustment can still increase power when the hypothesis test is based on
dividing the estimator by its standard error and rejecting the null hypothesis
when this ratio exceeds a threshold. This results from the fact that power is
related to the variance through the standard error in the denominator of the
test statistic. For example, even though the MCI trial is well balanced, there
is still an estimated 25% variance reduction from adjustment. When there
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are prognostic baseline variables, we recommend that covariate adjustment be
preplanned as the primary efficacy analysis.
If the outcome is binary, count, ordinal or time-to-event, then covariate ad-
justment can be done using estimators of, e.g., Moore and van der Laan (2009a),
Lu and Tsiatis (2011), Howard et al. (2012) and Dı́az et al. (2018). However,
robust variance estimators typically must be used, e.g., when constructing con-
fidence intervals or conducting hypothesis tests. The sandwich estimator could
be used as described by Tsiatis et al. (2008); alternatively, the nonparametric
bootstrap could be used. Because of these results for other outcome types, it
was surprising that when using ANCOVA it is unnecessary to use these robust
variance estimators (since as proved in Section 2.4.2 the standard, model-based
variance estimator for ANCOVA is already robust to arbitrary model misspec-
ification).
We assumed equal randomization probabilities to the two trial arms. If
unequal probabilities are used, then a robust variance estimator is needed for
ANCOVA.
We also assumed that the data vector for each participant is an indepen-
dent, identically distributed draw from an unknown distribution. This as-
sumption does not hold if stratified randomization or covariate-adaptive ran-
domization is used. For stratified randomization and some types of covariate-
adaptive randomization, Bugni et al. (2018) showed that if the covariates in
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the ANCOVA model are the indicators of the strata used in the randomization
procedure, then the ANCOVA estimator is consistent; furthermore, its model-
based variance estimator is consistent if the limiting probability of assignment
to each arm is 1/2 within each stratum. The previous sentence holds regard-
less of whether the true data generating distribution satisfies any of the AN-
COVA model assumptions. In general, adjusting for stratification variables is
recommended when using stratified randomization or covariate-adaptive ran-
domization (Lachin et al., 1988; Kahan and Morris, 2012; EMA, 2015). It is an
open question, to the best of our knowledge, as to what happens when more
variables than the stratification indicators are included in the ANCOVA model
under such randomization schemes, in terms of consistency of the ANCOVA
estimator and how to compute its asymptotic variance under arbitrary model
misspecification.
How to best pick the set of covariates to use in an adjusted estimator is a
challenging problem. The methods of Moore and van der Laan (2009a) and
Moore et al. (2011) use cross-validation, Bloniarz et al. (2016) and Tian et al.
(2019) use LASSO, and Wager et al. (2016) use a combination of regression and
cross-validation. All aspects of the covariate adjustment method need to be








The content of this chapter is reproduced from Wang et al. (2019) available
at https://arxiv.org/abs/1910.13954 and has been submitted to Jour-
nal of American Statistical Association for consideration.
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3.1 Introduction
A joint guidance document from the U.S. Food and Drug Administration
and the European Medicines Agency (FDA and EMA, 1998) states that “Pre-
trial deliberations should identify those covariates and factors expected to have
an important influence on the primary variable(s), and should consider how
to account for these in the analysis to improve precision and to compensate
for any lack of balance between treatment groups.” More recent regulatory
guidance documents also encourage consideration of baseline variables in or-
der to improve precision in randomized trials (EMA, 2015; FDA, 2019, 2020).
Though there is a rich statistical literature on model-robust methods to adjust
for baseline variables in randomized trials that use simple randomization, less
is known for trials that use other forms of randomization. This is a practi-
cal concern since, as discussed below, many clinical trials use other forms of
randomization.
“Covariate-adaptive randomization” refers to randomization procedures that
take baseline variables into account when assigning participants to study arms.
The goal is to achieve better balance across study arms in preselected strata of
the baseline variables compared to simple randomization (which ignores base-
line variables). E.g., balance on disease severity, a genetic marker, or another
variable thought to be correlated with the primary outcome could be sought.
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The simplest and most commonly used type of covariate-adaptive randomiza-
tion is stratified permuted block randomization (Zelen, 1974), referred to as
“stratified randomization” throughout, for conciseness.
Compared with simple randomization, covariate-adaptive randomization
can be advantageous in minimizing imbalance and improving efficiency (Efron,
1971; Pocock and Simon, 1975; Wei, 1978). Due to these benefits, covariate-
adaptive randomization has become a popular approach in clinical trials. Ac-
cording to a survey by Lin et al. (2015), 183 out of their sample of 224 ran-
domized clinical trials published in 2014 in leading medical journals used some
form of covariate-adaptive randomization. Stratified randomization was imple-
mented by 70% of trials in this survey. Another method for covariate-adaptive
randomization is the biased-coin design by Efron (1971), which we call “biased-
coin randomization” throughout. Other examples include Wei’s urn design
(Wei, 1978) and rerandomization (Morgan and Rubin, 2012). We only con-
sider the following two types of covariate-adaptive randomization: stratified
randomization and biased-coin randomization.
Concerns have been raised regarding how to perform valid statistical anal-
yses at the end of trials that use covariate-adaptive randomization. Adjusting
for stratification variables is recommended (Lachin et al., 1988; Kahan and
Morris, 2012; EMA, 2015). However, this recommendation is not reliably car-
ried out. Kahan and Morris (2012) sampled 65 published trials from major
34
CHAPTER 3. MODEL-ROBUST INFERENCE UNDER STRATIFIED
RANDOMIZATION AND COVARIATE ADJUSTMENT
medical journals from March to May 2010 and found that 41 implemented
covariate-adaptive randomization (among which 29 used stratified randomiza-
tion), but only 14 adjusted in the primary analysis for the variables used in the
randomization procedure. Furthermore, many results on how to conduct the
primary efficacy analysis in trials that use stratified randomization require
one to assume a correctly specified regression model, e.g., Shao et al. (2010);
Shao and Yu (2013); Ma et al. (2015, 2018); Yang et al. (2020). Our focus is on
model-robust estimators, i.e., estimators that do not require such an assump-
tion when there is no missing data or when outcome data are missing com-
pletely at random; when censoring depends on baseline variables, additional
assumptions are generally required.
Yang and Tsiatis (2001) showed that the analysis of covariance (ANCOVA)
estimator is consistent and asymptotically normal under simple randomiza-
tion, and that this holds under arbitrary misspecification of the linear regres-
sion model used to construct the estimator. Analogous results for the ANCOVA
estimator were shown by Bugni et al. (2018) under a variety of covariate-
adaptive randomization procedures that include stratified and biased-coin ran-
domization; however, their results only allow adjustment for the variables used
in the randomization procedure. The proofs of our results build on key ideas
from their work as described below. The results of Li and Ding (2020) and Liu
and Yang (2020) for the ANCOVA estimator are robust to arbitrary misspec-
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ification of the linear regression model; however, they use the randomization
inference framework while many clinical trials are analyzed using the super-
population inference framework (as done here); see Robins (2002) for a com-
parison of these frameworks. All of the results in this paragraph are for the
ANCOVA estimator, and so do not apply to logistic regression models for bi-
nary outcomes nor to commonly used models for time-to-event outcomes. Ye
and Shao (2020) derived asymptotic distributions for log-rank and score tests
in survival analysis under covariate-adaptive randomization; however, estima-
tion was not addressed.
For trials using stratified or biased-coin randomization, to the best of our
knowledge, it was an open problem to determine (in the commonly used su-
perpopulation inference framework and without making parametric model as-
sumptions) the large sample properties of estimators that involve any of the
following features: binary or time-to-event outcomes, adjustment for baseline
variables in addition to those in the randomization procedure, and missing data
under the missing at random assumption. This is the problem that we address,
and we think that each of the above features can be important in the analysis of
clinical trials. For example, binary and time-to-event outcomes are commonly
used in clinical trials. According to a survey by Austin et al. (2010) on trials
published in leading medical journals in 2007, 74 out of 114 trials involved bi-
nary or time-to-event outcomes. As we show in our data analyses, the addition
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of baseline variables beyond those used for stratified randomization can lead to
substantial precision gains. Handling missing data is also important in order
to avoid bias in treatment effect estimation.
Under regularity conditions, we prove that a large class of estimators is con-
sistent and asymptotically normally distributed in randomized trials that use
stratified or biased-coin randomization, and we give a formula for computing
their asymptotic variance. This class of estimators consists of all M-estimators
that are consistent under simple randomization. Examples are listed in Sec-
tion 3.4. We prove analogous results for the Kaplan-Meier (K-M) estimator
(Kaplan and Meier, 1958) of the survival function. Underlying these results is
our general technique for characterizing the large sample behavior of asymp-
totically linear estimators under stratified or biased-coin randomization, de-
scribed in Section 3.7.
Our theorems imply that under standard regularity conditions, whenever
an estimator in our class is consistent and asymptotically normally distributed
under simple randomization, then it is consistent and asymptotically normally
distributed under stratified (or biased-coin) randomization. Also, its influence
function is the same regardless of whether data is generated under simple,
stratified or biased-coin randomization. This can be advantageous since for
many estimators used to analyze randomized trials, their influence functions
have already been derived under simple randomization. An estimator’s in-
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fluence function can be input into our formula (3.5) to produce a consistent
variance estimator under stratified and biased-coin randomization.
As in the aforementioned work, we assume that the randomization proce-
dure and analysis method have been completely specified before the trial starts,
as is typically required by regulators (FDA and EMA, 1998; EMA, 2015; FDA,
2019, 2020).
In the next section, we describe three trial examples to which we apply our
methods. In Section 3.3, we describe our setup, notation and assumptions. We
present our main results in Section 3.4. In Section 3.5, we give example esti-
mators for continuous and binary outcomes to which our general results apply.
In Section 3.6, we present asymptotic results for the Kaplan-Meier estima-
tor for time-to-event outcomes. Trial applications are provided in Section 3.7.
Practical recommendations and future directions are discussed in Section 3.8.
3.2 Three completed trials that used strat-
ified randomization
In some cases, the outcomes in our analyses differ from the primary out-
comes in the corresponding trials. This is because we wanted similar outcomes
across trials for illustration.
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3.2.1 Buprenorphine tapering and illicit opioid
use (NIDA-CTN-0003)
The trial of “Buprenorphine tapering schedule and illicit opioid use” in the
National Drug Abuse Treatment Clinical Trials Network (NIDA-CTN-0003), is
a phase-3 randomized trial completed in 2005 (Ling et al., 2009). The goal was
to compare the effects of a short or long taper schedule after buprenorphine
stabilization of patients with opioid use disorder. Patients were randomized
into two arms: 28-day taper (control, 259 patients, 36% missing outcomes)
and 7-day taper (treatment, 252 patients, 21% missing outcomes), stratified
by maintenance dose (3 levels) measured at randomization. The outcome of in-
terest is a binary indicator of whether a participant’s urine tested at the end of
the study is opioid-free. In addition to the stratification variable, we adjust for
the following baseline variables: sex, opioid urine toxicology results, the Ad-
jective Rating Scale for Withdrawal (ARSW), the Clinical Opiate Withdrawal
Scale (COWS) and the Visual Analog Scale (VAS).
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3.2.2 Prescription opioid addiction treatment (NIDA-
CTN-0030)
The “Prescription Opioid Addiction Treatment Study” (NIDA-CTN-0030) is
a phase-3 randomized trial completed in 2013 (Weiss et al., 2011). The goal was
to determine whether adding individual drug counseling to the prescription of
buprenorphine/naloxone would improve outcomes for patients with prescrip-
tion opioid use disorder. Though this study adopted a 2-phase adaptive design,
we focus on the first phase, in which patients were randomized into standard
medical management (control, 330 patients, 10% missing outcomes) or stan-
dard medical management plus drug counseling (treatment, 335 patients, 13%
missing outcomes). Randomization was stratified by the presence or absence
of (i) a history of heroin use and (ii) current chronic pain, resulting in 4 strata.
The outcome of interest is the proportion of negative urine laboratory results
among all tests (treated as a continuous outcome between 0 and 1). Among all
5 urine laboratory tests during the first 4 weeks of phase I, if a patient missed
two consecutive visits, then the outcome is regarded as missing. We included
the following baseline variables in the analysis: randomization stratum, age,
sex and urine laboratory results.
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3.2.3 Internet-delivered treatment for substance
abuse (NIDA-CTN-0044)
The phase-3 randomized trial “Internet-delivered treatment for substance
abuse” (NIDA-CTN-0044) was completed in 2012 (Campbell et al., 2014). The
goal was to evaluate the effectiveness of a web-delivered behavioral interven-
tion, Therapeutic Education System (TES), in the treatment of substance abuse.
Participants were randomly assigned to two arms: treatment as usual (control,
252 participants, 19% missing outcomes) and treatment as usual plus TES
(treatment, 255 participants, 18% missing outcomes).
Randomization was stratified by site, patient’s primary substance of abuse
(stimulant or non-stimulant) and abstinence status at baseline. Unfortunately,
the available data set for this trial did not include the site variable. Our analy-
ses and claims in Section 3.7 assume that the only randomization strata are the
patient’s primary substance of abuse and abstinence status at baseline (4 levels
overall). Our theorems imply that ignoring one or more randomization stratum
variables leads to conservative variance estimates when using our variance for-
mulas, as explained in Section 3.8.
After randomization, each participant was followed for 12 weeks with 2
urine laboratory tests per week. The outcome of interest is the proportion of
negative urine lab results among all tests (treated as a continuous outcome
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between 0 and 1). If a participant missed visits of more than 6 weeks, the
outcome is regarded as missing. We adjust for randomization stratum and the
following additional baseline variables: age, sex and urine laboratory result.
We also analyze a second outcome: time to abstinence, defined as the time
to first two consecutive negative urine tests during the study. Censoring time
is defined as the first missing visit. We used the data from the first 6 weeks of
follow-up in our data analysis of this time-to-event outcome, during which 99%
of the events occurred.
3.3 Definitions and assumptions
3.3.1 Data generating distributions
We focus on two-arm randomized trials that use simple, stratified or biased-
coin randomization. Let n denote the sample size. For each participant i =
1, . . . , n, let Yi denote the primary outcome, Mi denote whether Yi is observed
(Mi = 1) or missing (Mi = 0), Ai denote study arm assignment (Ai = 1 if as-
signed to treatment and Ai = 0 if assigned to control), and Xi denote a vector
of baseline covariates. This notation is for real-valued outcomes, e.g. contin-
uous or binary outcomes. Modified definitions, assumptions, and results for
time-to-event outcomes are in Section 3.6.
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We use the Neyman-Rubin potential outcomes framework (Neyman et al.,
1990), which assumes the existence of potential outcomes Yi(0) and Yi(1) for
each participant i. These represent the outcome that would be observed under
assignment to study arm 0 or 1, respectively. Though using potential outcomes
introduces additional notation, it is needed in order to rigorously define the
data generating distributions under the different randomization procedures
that we consider. We make the following consistency assumption linking the
observed outcome Yi to the potential outcomes: Yi = Yi(Ai) = Yi(1)Ai + Yi(0)(1−
Ai) for each participant i. Also, letMi(a) be the indicator of whether participant
i would have a non-missing outcome if they get assigned to study arm a ∈
{0, 1}. We assume, analogous to the consistency assumption above, that Mi =
Mi(Ai) = Mi(1)Ai +Mi(0)(1− Ai).
For each participant i, we define the full data vector (including potential
outcomes, some of which are not observed) Wi = (Yi(1), Yi(0),Mi(1),Mi(0),Xi)
and the observed data vector Oi = (Ai,Xi, YiMi,Mi). The reason that the prod-
uct YiMi appears in the observed data vector Oi is to encode that whenever
the outcome is missing (Mi = 0), the outcome value Yi is not available in Oi
(since YiMi = 0). The data available to the analyst at the end of the trial are
O1, . . . ,On.
We make the following assumptions on the distribution of {W1, . . . ,Wn}:
Assumption 1.
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(i) Wi, i = 1, . . . , n are independent, identically distributed samples from an
unknown joint distribution P on W = (Y (1), Y (0),M(1),M(0),X).
(ii) Missing at random: M(a)⊥⊥Y (a)|X for each arm a ∈ {0, 1}, where ⊥⊥ de-
notes independence.
Throughout, we use E to denote the expectation with respect to distribution
P .
3.3.2 Randomization procedures: simple, strat-
ified, and biased-coin
First consider simple randomization, which assigns study arms A1, . . . , An
by independent Bernoulli draws each with fixed probability π of being 1, e.g.,
using a random number generator. By design, the draws are independent of
each other and of all participant characteristics measured before randomiza-
tion or not impacted by randomization. Therefore, we have that (A1, . . . , An) is
independent of (W1, . . . ,Wn), and that the observed data O1, . . . ,On are inde-
pendent, identically distributed.
Next consider stratified or biased-coin randomization, where treatment al-
location depends on predefined baseline strata, such as gender, age, site, dis-
ease severity, or combinations of these. We refer to the baseline strata that are
used in the randomization procedure as “randomization strata”. The baseline
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stratum of participant i is denoted by the single, categorical variable Si tak-
ing K possible values. For example, if randomization strata are defined by 4
sites and a binary indicator of high disease severity, then S has K = 8 pos-
sible values. Let Si denote the stratification variable for participant i and let
S = {1, . . . , K} denote the set of all K randomization strata. The goal of strati-
fied or biased-coin randomization is to achieve balance in each stratum; that is,
the proportion of participants assigned to the treatment arm is targeted to the
prespecified proportion π ∈ (0, 1), e.g. π = 0.5. Throughout, the stratification
variable S is encoded in the baseline covariate vector X using K − 1 dummy
variables that make up the first K − 1 components of X (which can include
additional baseline variables).
Stratified randomization uses permuted blocks to assign treatment. For
each randomization stratum, a randomly permuted block with fraction π 1’s
(representing treatment) and (1 − π) 0’s (representing control) is used for se-
quential allocation. When a block is exhausted, a new block is used.
Biased-coin randomization can be applied when π = 0.5 and it allocates
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participants sequentially by the following rule for k = 1, . . . , n:




i=1 (Ai − 0.5)I{Si = Sk} = 0
λ, if
∑k−1
i=1 (Ai − 0.5)I{Si = Sk} < 0
1− λ, if
∑k−1
i=1 (Ai − 0.5)I{Si = Sk} > 0
where λ ∈ (0.5, 1], I{Z} is the indicator function that has value 1 if Z is true and
0 otherwise, and by convention the first participant is assigned with probability
0.5 to each arm. Our results for biased-coin randomization assume that π = 0.5.
When comparing the three types of randomization procedures (simple, strat-
ified, or biased-coin), we assume that all use the same value of π. For the strati-
fied randomization and biased-coin designs, it follows by construction (and was
shown by Bugni et al., 2018) that the study arm assignments (A1, . . . , An) are
conditionally independent of the participant baseline variables and potential
outcomes (W1, . . . ,Wn) given the randomization strata (S1, . . . , Sn). Intuitively,
this is because the study arm assignment procedure only has access to the par-
ticipants’ randomization strata. Under stratified or biased-coin randomization,
the observed data vectors O1, . . . ,On are not independent.
Under any of the three randomization procedures, the observed data vec-
tors O1, . . . ,On are identically distributed; that is, the distribution of O1 is the
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same as that of O2, etc. Let P ∗ denote this distribution, i.e., the distribution
of a generic, observed data vector O = (A,X, Y M,M). This distribution is the
same for each of the three randomization procedures, and is that induced by
first drawing a single realizationW = (Y (1), Y (0),M(1),M(0),X) from the dis-
tribution P (see Assumption 1), then drawing A as an independent Bernoulli
draw with probability π of being 1, and lastly applying the consistency assump-
tions Y = Y (1)A + Y (0)(1 − A) and M = M(1)A + M(0)(1 − A) to construct Y ,
the (non)-missingness indicator M , and their product YM . The corresponding
expectation with respect to P ∗ is denoted E∗, which is used below. The claims
in this paragraph are proved in the Supplementary Material.
3.3.3 Targets of inference (estimands) and esti-
mators
For continuous and binary outcomes, our goal is to estimate a population
parameter ∆∗, which is a contrast between the marginal distributions of Y (1)
and Y (0). For example, ∆∗ can be defined as the population average treatment
effect E[Y (1)]− E[Y (0)].
We consider M-estimators of ∆∗ (van der Vaart, 1998, Ch. 5). Let θ =
(∆,βt)t denote a column vector of p+ 1 parameters where ∆ ∈ R is the param-
eter of interest and β ∈ Rp is a column vector of p nuisance parameters. We
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ψ(Ai,Xi, Yi,Mi;θ) = 0, (3.1)
where ψ is a column vector (with p + 1 components) of known functions. We
define ∆̂ to be the estimator of ∆∗. We assume that ψ(A,X, Y,M ;θ) does not
depend on the outcome Y when M = 0 (since then Y is missing). Many esti-
mators used in clinical trials, including all estimators defined in Section 3.5.1,
can be expressed as solutions to estimating equations (3.1) for an appropriately
chosen estimating function ψ.
For time-to-event outcomes, the K-M estimator of the survival curve is com-
monly used. Since it is not an M-estimator, our general result (Theorem 2) for
M-estimators below does not apply. We separately prove analogous results for
the K-M estimator; see Section 3.6.
We assume regularity conditions similar to the classical conditions that are
used for proving consistency and asymptotic linearity of M-estimators for inde-
pendent, identically distributed data, as given in Section 5.3 of van der Vaart
(1998). One of the conditions is that the expectation of the estimating equa-
tions
E∗[ψ(A,X, Y,M ;θ)] = 0, (3.2)
has a unique solution in θ, which is denoted as θ = (∆,βt)t. The other regular-
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ity conditions are given in the Supplementary Material.
We assume that the estimating equations ψ were chosen to ensure that the
property ∆∗ = ∆ holds. This property is generally needed to show consistency
of the M-estimator ∆̂ for ∆∗ under simple randomization, and has previously
been proved for all of the estimators in Section 3.5.1. In general, whether
the property ∆∗ = ∆ holds does not depend on the randomization procedure
(simple, stratified, or biased-coin randomization); this is because the property
depends only on ψ, P and P ∗.
Results in Section 5.3 of van der Vaart (1998) imply that under simple ran-
domization, given Assumption 1 and the regularity conditions in the Supple-
mentary Material, ∆̂ converges in probability to ∆ and is asymptotically nor-
mally distributed with asymptotic variance that we denote by Ṽ . We focus
on determining what happens under stratified or biased-coin randomization,
where our main result (Section 3.4) is that consistency and asymptotic nor-
mality still hold but the asymptotic variance may be smaller (and a consistent
variance estimator is given).
3.4 Main result for M-estimators
Consider the setup in Section 3.3.3, where the M-estimator ∆̂ is defined.
The proof of the following theorem (and all results in the paper) is given in the
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Supplementary Material:
Theorem 2. Assume the regularity conditions in the Supplementary Material,
∆∗ = ∆, and Assumption 1. Then under simple, stratified, or biased-coin ran-







IF (Ai,Xi, Yi,Mi) + op(1), (3.3)
where the influence function IF (A,X, Y,M) is the first entry of









For stratified and biased-coin randomization,
√
n(∆̂−∆∗) d−→ N(0, V ) for




E∗ {(A− π)IF (A,X, Y,M)|S}2
]
, (3.4)
where Ṽ = E∗{IF (A,X, Y,M)2} is the asymptotic variance under simple ran-
domization. The asymptotic variance V can be consistently estimated by for-
mula (3.5) below.
Theorem 2 implies that whenever an M-estimator ∆̂ is consistent and asymp-
totically normally distributed under simple randomization, then it is consistent
and asymptotically normally distributed under stratified (or biased-coin) ran-
domization with equal or smaller asymptotic variance. Also, its influence func-
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tion is the same regardless of whether data is generated under simple, strat-
ified, or biased-coin randomization. This can be advantageous since for many
estimators used to analyze randomized trials, their influence functions have al-
ready been derived under simple randomization; the last display in Theorem 2
gives a formula for calculating the asymptotic variances for these estimators
under the other two randomization procedures, in terms of the influence func-
tion.









Ai), our Theorem 2 is equivalent to Theorem 4.1 of Bugni et al. (2018) un-
der stratified or biased-coin randomization. In the special case of continuous
outcomes, if the ANCOVA estimator is used with X = S, then Theorem 2 is
equivalent to the result in section 4.2 of Bugni et al. (2018) under stratified
or biased-coin randomization, though their results also handle other types of
covariate-adaptive randomization.
Theorem 2 above extends the results of Bugni et al. (2018) to handle the
class of M-estimators, that is, estimators calculated by solving estimating equa-
tions (3.1). This includes, for example, the ANCOVA estimator that adjusts
for baseline covariates in addition to those used in the randomization proce-
dure (Example 1 of Section 3.5.1 below), the standardized logistic regression
estimator for binary outcomes (Example 2 of Section 3.5.1), and the DR-WLS
estimator (Example 3 of Section 3.5.1). This class of estimators also includes
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the inverse-probability-weighted estimator (IPW, Robins et al., 1994), the aug-
mented inverse probability weighted estimator (AIPW, Robins et al., 1994;
Scharfstein et al., 1999), the Mixed-effects Model for Repeated Measures es-
timator (MMRM, Mallinckrodt et al., 2003; Siddiqui et al., 2009; EMA, 2019),
and targeted maximum likelihood estimators (TMLE) that converge in 1-step
(van der Laan and Gruber, 2012), among others. Thus, Theorem 2 covers esti-
mators that handle various outcome types, repeated measures outcomes, miss-
ing outcome data, and covariate adjustment. Our proof relies on key ideas from
Lemmas B.1 and B.3 in the Supplement of Bugni et al. (2018).
We prove consistency of the following estimator for the asymptotic variance
V , which is the following empirical counterpart of the right side of (3.4):





En{(A− π)IF (A,X, Y,M)|S}2
]
, (3.5)
where Ṽn is the sandwich variance estimator of ∆̂ (Section 3.2 of Tsiatis, 2007),


























and En denotes expectation with respect to the empirical distribution of the
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observed data O1, . . . ,On.
3.5 Example estimators for continuous
and binary outcomes
3.5.1 ANCOVA, standardized logistic regression,
and DR-WLS
We give several examples of estimators that Theorem 2 applies to. For esti-
mators defined in Examples 1-3, the parameter of interest, i.e. ∆∗, is the aver-
age treatment effect defined as E[Y (1)]−E[Y (0)], and we denoteZ = (1, A,X t)t.
In Examples 1 and 2, we assume no missing data and we do not assume that
the working models, i.e., the linear regression model in Example 1 and the
logistic regression model in Example 2, are correctly specified.
Example 1. For continuous outcomes, the ANCOVA estimator ∆̂ancova for ∆∗
involves first fitting a linear regression working model E[Y |A,X] = β0 + ∆A +
βtXX using ordinary least squares and then letting ∆̂ancova be the estimate of ∆.
The ANCOVA estimator can be equivalently calculated by solving estimating
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equations (3.1) letting
ψ(A,X, Y,M ;θ) = {Y − (β0 + ∆A+ βtXX)}Z.
Example 2. For binary outcomes, the standardized logistic regression esti-
mator ∆̂logistic is calculated by first fitting a working model: P (Y = 1|A,X) =
expit(β0 +βAA+βtXX), where expit(x) = 1/(1+e−x), and getting the maximum




i=1{expit(β̂0 + β̂A +
β̂tXXi)− expit(β̂0 + β̂tXXi)}. Equivalently, the estimator ∆̂logistic is the solution
to estimating equations (3.1) letting
ψ(A,X, Y,M ;θ) =
 expit(β0 + βA + βtXX)− expit(β0 + βtXX)−∆
{Y − expit(β0 + βAA+ βtXX)}Z
 .
This estimator is mentioned as potentially useful in COVID-19 treatment and
prevention trials in a recent FDA guidance (FDA, 2020).
Example 3. When some outcomes are missing, then one can estimate ∆∗ by
the DR-WLS estimator, which generalizes the estimators in Examples 1 and 2.
However, due to missing data this estimator requires additional assumptions
(as is true for all estimators) described below. The DR-WLS estimator can be
used with binary or continuous outcomes. The estimator is calculated by first
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fitting the logistic regression working model:
P (M = 1|A,X) = expit(α0 + αAA+αtXX) (3.6)




t. Next, fit the following working model for the outcome given study
arm and baseline variables (from the generalized linear model family):
E[Y |A,X] = g−1(β0 + βAA+ βtXX), (3.7)
with weights 1/expit(α̂0 + α̂AAi + α̂tXXi) using only the data with Mi = 1. Here
the inverse link function is g−1(x) = x for continuous outcomes and g−1(x) =






{g−1(β̂0 + β̂A + β̂tXX)− g−1(β̂0 + β̂tXX)}.
The DR-WLS estimator can be expressed as the solution to estimating equa-
tions (given in the Supplementary Material) of the general form (3.1). For the
DR-WLS estimator, we assume that at least one of the two working models
(3.6) and (3.7) is correctly specified, and inf(a,x)∈(A,X ) P (M = 1|a,x) > 0, where
(A,X ) is the support of (A,X).
The ANCOVA estimator and the standardized logistic regression estimator
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are special cases of the DR-WLS estimator. If there are no missing data, which
means Mi = 1 for i = 1, . . . , n, and the regression weights used to fit (3.7)
are constant, then ∆̂DR−WLS reduces to ∆̂ancova for continuous outcomes and
to ∆̂logistic for binary outcomes. The DR-WLS estimator can be generalized to
allow the addition of interaction terms in the model (3.7).
3.5.2 Asymptotic Results for Estimators in Ex-
amples 1-3
Under simple randomization and assuming that ∆∗ = ∆, consistency and
asymptotic normality for the estimators in Examples 1-3 have been proved by
Yang and Tsiatis (2001); Scharfstein et al. (1999); Robins et al. (2007), respec-
tively. Under stratified or biased-coin randomization, Theorem 2 applies to
these estimators since each is an M-estimator. In particular, under the condi-
tions in the theorem, each of the three estimators is consistent and asymptoti-
cally normal with asymptotic variance that is consistently estimated by (3.5).
Under the additional conditions (a)-(c) listed in the corollary below, for each
estimator in Examples 1-3, its asymptotic variance is the same regardless
of whether simple, stratified, or biased-coin randomization is used; also, the
asymptotic variance is consistently estimated by the sandwich variance esti-
mator Ṽn. Under such conditions, the estimators and their corresponding sand-
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wich variance estimators can be used to perform hypothesis tests and construct
confidence intervals that are asymptotically correct.
Recall that we assume throughout that S is encoded by dummy variables in
X.
Corollary 1. Assume that ∆∗ = ∆, the regularity conditions in the Supple-
mentary Material, and Assumption 1. Consider the ANCOVA estimator or the
standardized logistic regression estimator. If any of the conditions (a)-(c) below
holds, then under simple, stratified, or biased-coin randomization, the estimator
is consistent and asymptotically normally distributed with asymptotic variance
V = Ṽ ; furthermore, the sandwich variance estimator is consistent. Conditions:
(a) π = 0.5;
(b) the outcome regression model (3.7) includes indicators for the randomiza-
tion strata and also treatment-by-randomization-strata interaction terms;
(c) the outcome regression model (3.7) is correctly specified.
For the special case of the ANCOVA estimator with X = S, Corollary 1 with
condition (a) or (b) was proved by Bugni et al. (2018). The claims in Corollary 1
also hold for the the DR-WLS estimator if at least one of the two working mod-
els (3.6) and (3.7) is correctly specified and inf(a,x)∈(A,X ) P (M = 1|a,x) > 0, where
(A,X ) is the support of (A,X).
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3.6 Estimators involving time-to-event
outcomes
3.6.1 Notation and Assumptions
For time to event outcomes, we use slightly modified notation and assump-
tions compared to above. We assume that the outcome is right-censored. Let
Yi denote the failure time and Mi denote the censoring time. Other variables
including Ai,Xi and the potential outcomes Yi(a),Mi(a) for a = 0, 1 are defined
analogously as in Section 3.3. For each participant i ∈ {1, . . . , n}, we observe
(Ai,Xi, Ui, δi), where Ui = min{Yi,Mi} and δi = I{Yi ≤ Mi}. We further de-
fine a restriction time τ such that the time window t ∈ [0, τ ] is of interest. We
define P ∗ and E∗ analogously as in Section 3.3.2, except here they represent
the distribution and expectation, respectively, for a single observed data vector
(A,X, U, δ).
The following assumption is made in place of Assumption 1:
Assumption 1’.
(i) Wi, i = 1, . . . , n are independent, identically distributed samples from an
unknown joint distribution P on W = (Y (1), Y (0),M(1),M(0),X).
(ii) Censoring completely at random: M(a)⊥⊥Y (a) for each arm a ∈ {0, 1}.
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(iii) P (min{Y (a),M(a)} > τ) > 0 for each a = 0, 1.
Compared with Assumption 1, Assumption 1’(i) is the same as Assumption
1(i), and Assumption 1’(ii) assumes censoring completely at random instead of
missing at random. This modification of the assumption on missing data is
because we consider the K-M estimator and its consistency generally requires
Assumption 1’(ii). Assumption 1’(iii) is often made in survival analysis, which
states that there is a positive probability that both the failure time and censor-
ing time occur after τ (under each study arm assignment).
3.6.2 Kaplan-Meier estimator under simple, strat-
ified, and biased-coin randomization
One commonly-used method for survival analysis is the K-M estimator. The
goal is to estimate the survival curve {S(a)0 (t) : t ∈ [0, τ ]} for each a = 0, 1, where
S
(a)
0 (t) = P (Y (a) > t). This represents the survival curve if everyone in the








i=1 δiI{Ai = a}I{Ui = Tj}∑n
i=1 I{Ai = a}I{Ui ≥ Tj}
)
,
where {Tj, j = 1, . . . ,mn} is the list of unique observed failure times.
While the K-M estimator does not adjust for any baseline variable, its vari-
ance under simple randomization is typically different than under stratified or
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biased-coin randomization, and this is not accounted for by standard methods
for estimating its variance. Specifically, the standard method for variance esti-
mation will typically overestimate the K-M variance under stratified or biased-
coin randomization, leading to wasted power. Our variance estimator below
avoids this problem. Since the K-M estimator estimates a survival function
rather than a real number or a vector, our Theorem 2 on M-estimators does
not apply. The following theorem gives the asymptotic distribution of the K-M
estimator under our three different types of randomization. It involves the in-
fluence function IF (a)(Ai, Ui, δi; t) for the K-M estimator under simple random-
ization (Kosorok, 2008, Section 4.2), which is also given in the Supplementary
Material.
Theorem 3. Given Assumption 1’, under simple, stratified, or biased-coin ran-









IF (a)(Ai, Ui, δi; t) + op∗(1), (3.8)
where op∗(1) represents a sequence of random variables converging to 0 in prob-
ability uniformly over t ∈ [0, τ ].





n (t) − S(a)0 (t)) : t ∈ [0, τ ]} converges weakly to a mean 0, tight Gaussian
process with covariance function V (a)(t, t′) defined in the Supplementary Mate-
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rial, which has the following property: for any t ≤ τ ,






(A− π)IF (a)(A,U, δ; t)|S
}2]
, (3.9)
where Ṽ (a)(t, t) is the asymptotic variance under simple randomization. V (a)(t, t)
can be consistently estimated as described in the Supplementary Material.
Analogous to Theorem 2, Theorem 3 implies that the influence function of
the K-M estimator is the same under simple, stratified, and biased-coin ran-
domization. The above theorem implies that under stratified or biased-coin
randomization, the K-M estimator is consistent and asymptotically normally
distributed with equal or smaller asymptotic variance than under simple ran-
domization. The asymptotic covariance function of the K-M estimator under
stratified or biased-coin randomization is given in Appendix C of the Supple-
mentary Material. It can be used to construct pointwise confidence intervals
and a simultaneous confidence band.
The challenge in proving Theorem 3 is that the traditional tool for deriv-
ing asymptotic normality in survival analysis, i.e., martingale central limit
theorems such as Theorem II.5.1 of Andersen et al. (2012) or Theorem 5.1.1
of Fleming and Harrington (2011), is not applicable here because of the depen-
dence among data points introduced by stratified or biased-coin randomization.
To overcome the above difficulty, in the proof of Theorem 3 we first developed a
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central limit theorem for sums of random functions under stratified randomiza-
tion (Lemma 5 in the Supplementary Material) based on the empirical process
results of Shorack and Wellner (2009) combined with generalizations of the
techniques from Bugni et al. (2018). We then proved Theorem 3 by generaliz-
ing the arguments in our proof of Theorem 2 to handle random functions. We
conjecture that, using our central limit theorem, Theorem 3 can be general-
ized to apply to other estimators of survival functions, such as the covariate-
adjusted estimators proposed by Lu and Tsiatis (2011); Zhang (2015), which
may improve precision even further.
3.6.3 Other estimators for time-to-event outcomes
Another parameter of interest is the restricted mean survival time, defined
as ∆∗ = E[min{Y (1), τ}−min{Y (0), τ}]. One covariate adjusted estimator of the
restricted mean survival time is the augmented inverse probability weighted
(AIPW) estimator of Moore and van der Laan (2009b). This estimator is an
M-estimator, to which our Theorem 2 applies. When the survival probability at
a given time point is the parameter of interest, one can use the K-M estimator
or the method from Moore and van der Laan (2009b).
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3.7 Clinical trial applications
3.7.1 Binary and continuous outcomes
Table 3.1 summarizes our data analyses involving binary and continuous
outcomes. The outcome is binary for NIDA-CTN-0003 and is continuous for
NIDA-CTN-0030 and NIDA-CTN-0044. In all cases, the target of inference is
the average treatment effect defined as E[Y (1)]− E[Y (0)].
All missing baseline values were imputed by the median for continuous
variables and mode for binary or categorical variables. The only estimator in
Table 3.1 that adjusts for missing outcomes is the DR-WLS estimator; all other
estimators omit data from the participants with missing outcomes. Negative
(positive) estimates are in the direction of clinical benefit (harm). For all esti-
mators presented in Table 3.1, the 95% confidence interval (CI) is constructed
using the normal approximation with variance calculated from formula (3.5).
For NIDA-CTN-0003, the outcome is binary and “adjusted estimator” in
Table 1 refers to the standardized logistic regression estimator. The unad-
justed point estimate is −0.104 with 95% CI (−0.204,−0.004). If randomization
strata and additional baseline variables are adjusted for (as in the row “Ad-
justed estimator (X)” in Table 1), the point estimate is unchanged but the 95%
CI (−0.184,−0.024) is substantially smaller. The corresponding variance reduc-
tion due to covariate adjustment, defined as one minus the variance ratio of
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Table 3.1: Summary of clinical trial data analyses with each cell giving the
point estimate and 95% CI of an estimator. Each row is for a different estima-
tor. “Adjusted estimator” refers to the standardized logistic estimator for the
trial with binary outcome (column 2) and to the ANCOVA estimator for the tri-
als with continuous outcomes (columns 3 and 4). The variable in parentheses
after the estimator name indicates which variables (if any) are adjusted for,
with S denoting the randomization strata only andX denoting the randomiza-
tion strata and additional baseline variables.
Clinical Trial:
NIDA-CTN-0003 NIDA-CTN-0030 NIDA-CTN-0044
Unadjusted estimator -0.104(-0.204, -0.004) 0.015(-0.023, 0.052) -0.093(-0.149, -0.038)
Adjusted estimator (S) -0.110(-0.209, -0.009) 0.015(-0.022, 0.052) -0.089(-0.145, -0.033)
Adjusted estimator (X) -0.104(-0.184, -0.024) 0.012(-0.022, 0.046) -0.087(-0.142, -0.032)
DR-WLS estimator (X) -0.099(-0.180, -0.019) 0.012(-0.022, 0.045) -0.091(-0.148, -0.035)
“Adjusted estimator (X)” to the unadjusted estimator, is 36%. This is equiv-
alent to needing 36% fewer participants to achieve the same power as a trial
that uses the unadjusted estimator, asymptotically.
NIDA-CTN-0030 and NIDA-CTN-0044 had continuous-valued outcomes and
“Adjusted estimator” in Table 1 refers to the ANCOVA estimator. Covariate
adjustment brings 17% and 3% variance reduction for NIDA-CTN-0030 and
NIDA-CTN-0044, respectively, compared to the unadjusted estimator. In all
cases, the variance reduction from covariate adjustment is larger when the
baseline variables are more strongly prognostic for (i.e., more strongly corre-
lated with) the outcome.
In all three trials, the variance reduction due to adjusting for baseline vari-
ables beyond S, defined by one minus the variance ratio of “adjusted estimator
(X)” and “adjusted estimator (S)”, is the same (to the nearest percent) as the
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corresponding variance reduction comparing “adjusted estimator (X)” to the
unadjusted estimator. This is expected for the ANCOVA estimator since Bugni
et al. (2018) showed that “adjusted estimator (S)” and the unadjusted estima-
tor are asymptotically equivalent when the randomization probability π = 0.5.
Also, in all three trials, the “DR-WLS estimator (X)”, which handles missing
outcomes under the missing at random assumption, has a similar point esti-
mate and 95% CI compared to “adjusted estimator (X)”, which omits missing
outcomes. We recommend using the DR-WLS estimator in practice since it
is consistent under weaker assumptions than the other estimators considered
here.
We next compare the estimated variance (and resulting confidence inter-
vals) based on the sandwich variance estimator versus the variance estimator
(3.5). For the unadjusted estimator, using the sandwich variance estimator in-
stead of formula (3.5) may lead to conservative variance estimates, as implied
by Theorem 2. For example, for NIDA-CTN-0044, the 95% CI of the unadjusted
estimator constructed by formula (3.5) is (−0.149,−0.038), while the 95% CI
calculated using the sandwich variance formula is (−0.162,−0.025), which is
23% wider. The former 95% CI is asymptotically correct assuming outcomes
are missing completely at random, an assumption that is generally needed for
the the unadjusted estimator to be consistent. Furthermore, the variance of
the unadjusted estimator calculated by formula (3.5) (which is consistent) is
65
CHAPTER 3. MODEL-ROBUST INFERENCE UNDER STRATIFIED
RANDOMIZATION AND COVARIATE ADJUSTMENT
34% smaller than the variance calculated by the sandwich variance estimator
(which is conservative). In contrast, for the adjusted estimator or the DR-WLS
estimator, since all three trials have randomization probabillity π = 0.5, the
sandwich variance estimator is not conservative; this follows from Corollary 1.
3.7.2 Time-to-event outcome
Figure 3.1 presents the K-M estimator for time-to-abstinence in the treat-
ment group as defined in Section 3.2.3 for study NIDA-CTN-0044. We esti-
mated the variance of the K-M estimator in two different ways: one ignored the
stratification variable and was the estimated variance returned by the “surv-
fit” function in R; the other used our proposed variance formula that takes the
stratification into account. For each of the two variance estimators, we con-
structed corresponding point-wise confidence intervals for the K-M estimator.
While Figure 3.1 shows that confidence intervals based on different vari-
ance estimators are very close to each other, there are variance reductions due
to accounting for stratification, which can be translated into sample size re-
duction needed to achieve the desired power. The variance reduction ranges
from 1% to 12% as we consider the survival function at different time points.
Among all time points, the first time point (one week after randomization) has
the greatest variance reduction. The variance formula (3.9) from Theorem 3 ac-
counts for the improved precision due to stratified randomization (unlike stan-
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Figure 3.1: The K-M estimator of survival function for NIDA-CTN-0044 treat-
ment group. The solid line is the estimated survival function. Dashed and
dotted lines, respectively, represent confidence intervals using the standard
method and confidence intervals accounting for randomization strata using
(3.9); the dashed and dotted lines are very similar and almost coincide. “Vari-
ance Reduction” and the associated percentages represent the variance reduc-
tion due to accounting for stratified randomization using (3.9).
dard methods that ignore stratification variables); this can be used to construct
more powerful hypothesis tests based on the K-M estimator divided by its stan-
dard error. The corresponding figure and results for the control group are given
in the Supplementary Material and are qualitatively similar to those described
above for the treatment group.
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3.8 Discussion
The primary efficacy analysis in confirmatory randomized trials is typically
based on a treatment effect estimator that is asymptotically linear under sim-
ple randomization; i.e., for an appropriately chosen influence function IF , the
estimator has the form (3.3) when estimating a scalar/vector or (3.8) when es-
timating a function such as a survival curve. All estimators in this paper have
this property, and we proved for each estimator covered by Theorems 2-3 that
under stratified and biased-coin randomization, it is asymptotically linear with
the same influence function as under simple randomization. We then gave for-
mulas (3.4) and (3.9) for the asymptotic variance under stratified (and biased-
coin) randomization in terms of the influence function.
Though our theorems cover a variety of estimators used to analyze random-
ized trials, they do not handle every estimator. However, our results point to
a general approach for deriving the asymptotic behavior under stratified and
biased-coin randomization of any estimator that is known to be asymptotically
linear under simple randomization. The approach is to (a) conjecture that un-
der stratified and biased-coin randomization it is asymptotically linear with the
same influence function as under simple randomization; (b) prove this, which
may need to be tailored to the estimator, e.g., using techniques as shown in the
Supplementary Material for M-estimators and the K-M estimator; (c) apply re-
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sults from the Supplementary Material (Proposition 1 or Lemma 5) to show
that the asymptotic variance is given by (3.4) for scalar/vector parameters or
by (3.9) for functions. An area of future research is to apply this approach to
the estimators of Lu and Tsiatis (2011); Zhang (2015) that use covariate ad-
justment to improve precision of the K-M estimator.
Our asymptotic results, just as many asymptotic results under the com-
monly used superpopulation inference framework for randomized trials, as-
sume that the number of randomization strata is fixed and the number of
participants in each stratum goes to infinity. This may be a reasonable ap-
proximation when no stratum has a small number of participants. In our data
examples, the smallest stratum has 49 participants. An area of future research
is to consider cases where some randomization strata have few participants.
In our data analyses of NIDA-CTN-0044, the stratification variable “site”
was not available in our data set. It was therefore neither used in the esti-
mators nor in the corresponding variance estimates. The variance formulas
(3.4) and (3.9) in this case are asymptotically conservative. This is because
the outer expectation in the rightmost terms of these formulas are unchanged
or decreased if S is replaced by a coarsening of S (defined as merging sev-
eral randomization strata together in a preplanned way, in the analysis); this
follows from the conditional Jensen’s inequality. This result may be useful
more generally, e.g., when some strata are so small compared to the sample
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size that stratum-specific evaluation of the empirical means En in (3.5) and
the corresponding estimator for (3.9) cannot be reliably done. In such cases
a pre-planned, coarsened stratum indicator could be used and the resulting
hypothesis test would still control Type I error, asymptotically.
Stratified randomization is related to stratified sampling designs, also called
“two-phase sampling” (Sen, 1988; Breslow and Wellner, 2007; Bai et al., 2013).
To the best of our knowledge, asymptotic results for these designs do not di-
rectly apply to our problem; a key difference is that asymptotic results for
stratified sampling designs often involve finite population inference (commonly
used in survey sampling), while here we use superpopulation inference (com-
monly used in analyzing randomized trials).
We provide R functions to calculate the variance for estimators including






The content of this chapter is reproduced from Wang et al. (2020) available
at https://doi.org/10.1111/biom.13369.
4.1 Introduction
Common principal component analysis (CPCA) is an approach that simul-
taneously models multiple covariance matrices. It extends the idea of principal
component analysis by assuming all covariance matrices share the same set of
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eigenvectors. Since it was first introduced by Flury (1984), CPCA has been ex-
tensively applied in various fields including statistics (Gu, 2016; Pepler et al.,
2016), finance (Goyal et al., 2008; Xu et al., 2019), and computer science (Ye
et al., 2012; Hadjipantelis et al., 2015).
Extensions of CPCA have been investigated from multiple angles. Flury
(1987) proposed partial common principal component analysis (PCPCA), where
only a proportion of the eigenvectors was assumed to be shared across covari-
ance matrices and the rest to be individual-specific. Another direction relaxed
the Gaussianity assumption in CPCA, resulting in asymptotic theory for non-
Gaussian distributions (Boik, 2002; Hallin et al., 2010). Other extensions in-
clude Bayesian approaches (Hoff, 2009), algorithm acceleration (Browne and
McNicholas, 2014) and modifications for high-dimensional data (Franks and
Hoff, 2019). Among these extensions of CPCA, PCPCA continues to be appeal-
ing, as it relaxes the assumption of a completely common eigenspace across
matrices while partially preserving the straightforward interpretation of com-
mon eigenvectors, i.e., eigenvectors shared across matrices. Related work on
this topic includes Krzanowski (1984), Schott (1999), Boik (2002), Lock et al.
(2013) and Pepler et al. (2016).
In spite of these extensions, some questions related to PCPCA remain unan-
swered. Given the number of common eigenvectors, how one can identify the
common eigenvectors from a pool of eigenvectors requires further investiga-
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tion. Flury (1987) assumed that “some order of the common components is
defined”. Some of the literature assumed that the common eigenvectors are
those associated with the largest eigenvalues across all covariance matrices
(Schott, 1999; Crainiceanu et al., 2011). However, common eigenvectors may
be associated with small eigenvalues, or the corresponding eigenvalue of a com-
mon eigenvector ranks differently across matrices. This question becomes more
challenging if the number of common eigenvectors is unknown or the data is
not Gaussian distributed. Regarding these points, Pepler et al. (2016) devel-
oped a non-parametric method to select the common eigenvectors in the special
case of two covariance matrices. With multiple asymmetric matrices as the re-
sponse, Lock et al. (2013) proposed a linear model to identify latent factors that
explain the joint and individual data variation (JIVE) and Zhou et al. (2016)
generalized JIVE to a common and individual feature extraction (CIFE) frame-
work. None of these methods, however, studied the asymptotic properties.
In this paper, we propose a semiparametric PCPCA approach, which can
consistently estimate the common eigenvectors, without making any assump-
tions on the ranks of eigenvalues that are associated with common eigenvec-
tors. Our method builds on an idea from Krzanowski (1984), where a semipara-
metric approach was proposed in the context of CPCA. We extend this idea to
semiparametric PCPCA and provide asymptotic results for our methods as the
number of matrices, or the number of samples to estimate each matrix, goes to
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infinity (both with fixed dimension). If the number of samples goes to infinity,
our results do not require the data to be Gaussian distributed. When the num-
ber of common eigenvectors is unknown, we develop a sequential testing proce-
dure, which effectively controls the type I error for Gaussian distributed data.
As shown in the simulation study, our method outperforms existing methods
in estimating the common eigenvectors in a variety of scenarios.
In the next section, we introduce PCPCA. In Section 4.3, we present our pro-
posed semiparametric method to identify the common eigenvectors. We eval-
uate the performance of our proposed method through simulation studies in
Section 4.4. An application to an fMRI data set is provided in Section 4.5.
Section 4.6 summarises this paper and discusses future directions.
4.2 Model and assumptions
We consider a data set, {yit}, for t ∈ {1, . . . , T} and i ∈ {1, . . . , n}, where
yit ∈ Rp are independent and identically distributed random samples from a
p-dimensional distribution with mean zero and covariance matrix Σi. In our
application example, yit is a sample of brain fMRI measurements of p regions
from subject i at time point t. We assume that Σi satisfies the following partial
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where {λij}pj=1 are the eigenvalues of covariance matrix Σi and k is the largest
integer such that formulation 4.1 holds. The γj, for j = 1, . . . , k, are the
unit-length common eigenvectors across subjects. Let Γ = (γ1, . . . ,γk) ∈ Rp×k
(k ≤ p) be the orthonormal matrix of the common eigenvectors. The ril, for
l = 1, . . . , p− k, are unit-length individual-specific eigenvectors of subject i. Let
Ri = (ri1, . . . , ri,p−k) ∈ Rp×(p−k) be the orthonormal matrix of the individual-
specific eigenvectors. We assume that Ri is orthogonal to Γ, i.e., Γ>Ri = 0. Let




il . Then, the PCPC model (4.1)
can be reformulated as:
Σi = ΓΛiΓ
> + Ψi. (4.2)
First proposed by Flury (1987), the PCPC model has an interpretation anal-
ogous to CPCA. A CPC, defined by γjγ>j for j = 1, . . . , k, is shared across all
matrices. We emphasize that our definition of CPC is different from Flury
(1984) (or the principal component in PCA) where a CPC is defined as γ>j yit,
since we focus on the shared covariance structure across matrices instead of
individual-specific eigenvalues. For example, in our application, a CPC repre-
sents a functional brain network in the sense that it represents correlations in
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functional brain measures consistent across subjects. The corresponding diag-
onal entry of Λi is interpreted as the variation of the CPC in subject i. On the
other hand, Ψi is the individual-specific model component, which varies across
subjects. A toy example of the PCPC model with p = 4 and k = 2 is shown in
Figure 4.1.
Figure 4.1: An example of the PCPC model. Each covariance matrix consists
of two CPCs and an individual structure. Each CPC has rank 1 and norm 1.
Our goal is to both find k and estimate Γ consistently, as either n → ∞ or
T → ∞, with p fixed. When estimating Γ, existing methods, such as Schott
(1999) and Crainiceanu et al. (2011), assumed that CPCs are associated with
the largest eigenvalues across all covariance matrices. This is a restrictive as-
sumption, since the corresponding eigenvalue of a CPC may rank consistently
low or differently across matrices. For instance, our toy example in Figure 4.1
shows that CPCs are associated with small eigenvalues in matrices 1 and 2, but
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with large eigenvalues in matrix n. In addition, in many scientific applications,
there is no priori reason to assume that the variation explained by the common
components dominates the variation explained by the individual-specific com-
ponents. For this reason, we do not make any assumptions regarding the rank
of CPC-related eigenvalues.
The PCPC model shares some common features with existing partial infor-
mation decomposition methods, but there exist major differences. Crainiceanu
et al. (2011) provided a population value decomposition (PVD) model where
common eigenvectors are extracted from concatenated individual eigenvectors.
This procedure presumes that common inter-subject components are associ-
ated with the largest individual eigenvalues. Moreover, the approach does not
consider group level diagonalization as a goal. Lock et al. (2013) introduced
the JIVE model, which decomposes information from multiple data sources
into common components and individual components. Zhou et al. (2016) gen-
eralized the JIVE model by a CIFE framework, which has the same objective
function as JIVE. Unlike the PCPC model, the common components identified
by JIVE and CIFE are not unique, which can make them hard to interpret in
practice. Furthermore, PVD, JIVE and CIFE are empirical methods with no
asymptotic guarantees.
More recently, Wang et al. (2019) proposed a common reducing subspace
model, which assumes Σi = ΓΩ0Γ> + Γ̃ΩiΓ̃>, where (Γ, Γ̃) ∈ Rp×p forms an
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eigenbasis and Ω0 ∈ Rk×k,Ωi ∈ R(p−k)×(p−k), i = 1, . . . , n are positive definite
matrices. This model can be reformulated as Σi = ΓΛΓ> + Ψi, where Λ ∈ Rk×k
is a positive definite diagonal matrix shared across i and Ψi ∈ Rp×p is a positive
semi-definite matrix orthogonal to Γ with rank p−k. Compared with the PCPC
model (4.1), this model requires Λi ≡ Λ, and is hence a special case of the PCPC
model.
To achieve the identifiability of Γ and the consistency of our proposed esti-
mator, for the PCPC model (4.1), we impose the following assumptions for the
asymptotics when n→∞.
Assumption A (for n→∞):
1. T and p are fixed with T > 0 and p > 1.
2. Each (λi1, . . . , λik), i ∈ {1, . . . , n}, is an independent and identically dis-
tributed random sample from a distribution with finite mean (λ∗1, . . . , λ∗k)
and finite variance. Furthermore, elements of (λi1, . . . , λik) are indepen-
dent of each other.
3. Each Ψi, i ∈ {1, . . . , n}, is an independent and identically distributed ran-
dom sample from a distribution with finite mean Ψ∗ and finite second-
order moment. Both Ψi and Ψ∗ are symmetric positive semi-definite ma-
trices with rank p− k and are orthogonal to Γ.
4. The matrix ΓΛ∗Γ>+Ψ∗ has distinct eigenvalues, where Λ∗ = diag{λ∗1, . . . , λ∗k}.
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5. For each i ∈ {1, . . . , n}, yit is normally distributed given Σi.
To the best of our knowledge, we are the first to provide asymptotic results
as the number of matrices goes to infinity. Different from the literature where
n is fixed (Flury, 1987; Boik, 2002; Pepler et al., 2016; Wang et al., 2019), As-
sumptions A (2) and (3) assume (λi1, . . . , λik) and Ψi are random variables in-
stead of fixed parameters, since otherwise, the number of parameters would
explode as n increases. Assumption A (4) is required for identifiability of Γ
in matrix perturbation theory. The Gaussian assumption in Assumption A (5)
is made for convenience and is stronger than required for our results. For the
proof, we only need the fourth-order moment of yit to be the same as the fourth-
order moment of a Gaussian distribution, with mean 0 and covariance Σi.
In some cases, n is small but T is large. For example, in fMRI data analysis,
the number of subjects may be small, but subjects may have long fMRI scans.
In other measures with rapid sampling, such as electroencephalograms, this is
frequently the case. For such data sets, we prove a similar asymptotic theory
as T → ∞ with n and p fixed. This asymptotic theory requires the following
assumptions.
Assumption B (for T →∞):
1. n and p are fixed with n > 1 and p > 1.
2. For each i ∈ {1, . . . , n}, (λi1, . . . , λik) and Ψi are fixed.
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3. The eigenvalues of
∑n
i=1 Σi/n are distinct.
4. The fourth-order moment of yit is bounded for i = 1, . . . , n.
Assumption B (2) implies that the asymptotics are conditional on Σi, i =
1, . . . , n. The reason to pursue conditional asymptotics is that n is fixed and
inference on these specific n distributions is of interest. Unlike Assumption
A where a Gaussian distribution is assumed, Assumption B is semiparamet-
ric, since it does not put constraints on higher-order moments, except that the
fourth-order moment is bounded. Compared with existing asymptotic results
for T → ∞, Assumption B is weaker. Flury (1987) and Schott (1999) both as-
sumed that {yit} are normally distributed. Boik (2002) provided asymptotic
results for non-normal data, but modeled eigenvalues as known smooth func-
tions of parameters. Though Pepler et al. (2016) and Hallin et al. (2010) relaxed
Assumptions B (3) and (4), the former work only focused on the case when n = 2
and the latter was for CPCA.
In addition to Assumption A or Assumption B, we also assume that {yit}, t =
1, . . . , T are independent of each other. However, in many real-world appli-
cations, such as our fMRI data example, {yit} can be temporarily correlated.
We consider a generic constraint on the temporal correlation that, for t′ < t,
E[yity
>
it′ ] = Dt−t′ where Dt−t′ is a diagonal matrix and Dt−t′ = 0 if t > t′ + c
for some constant c. This assumed constraint is satisfied for many time series
models, including Bickel and Gel (2011) and Guo et al. (2016), and approxi-
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mately satisfied under the auto-regressive model. Under this assumption, our
theoretical results for n→∞ still hold. Alternatively, when T →∞, under the
same assumption, one can adopt an auto-regressive moving-average (ARMA)
model for pre-whitening {yit} to remove temporal dependence, which is com-
monly used in fMRI data analysis (Lindquist et al., 2008; Olszowy et al., 2019).
4.3 Estimation
In this section, we introduce our estimation procedure under two scenarios:
(1) the number of CPCs is known and (2) the number of CPCs is unknown.
When the number of CPCs is known, we prove that our proposed estimator of
the common eigenvectors is consistent. When the number of CPCs is unknown,
the estimation procedure has two steps: we first use a sequential testing pro-
cedure to estimate the number of CPCs, and then calculate our proposed esti-
mator using the estimated number of CPCs.
4.3.1 The number of CPCs is known
When the number of CPCs is known, we propose to estimate Γ in two steps:
first getting p CPC candidates for Γ, denoted as Γ̂candi ∈ Rp×p, and then selecting
k columns from Γ̂candi as Γ̂ ∈ Rp×k.









it/T is the sample covariance matrix of subject i. The
columns of Γ̂candi are ordered in a way that the corresponding eigenvalue of
each eigenvector is decreasing. We first define the consistency of an eigenvector
estimator.
Definition 1. Let {xs : s = 1, 2, . . . } denote a series of random vectors in Rp
with `2-norm 1; that is ‖xs‖2 = 1 for all s. Let x be a vector in Rp such that
‖x‖2 = 1. As s → ∞, xs is consistent to x if |〈xs,x〉|
P−→ 1, where 〈·, ·〉 is the
inner product defined in Rp and P−→ denotes convergence in probability.
Under Definition 1, the following theorem shows that k out of p columns of
Γ̂candi are consistent estimators of the columns of Γ as n or T goes to infinity,
which is a direct generalization of spectral properties of S.
Theorem 4. Assume the PCPC model (4.1) holds.
1. Under Assumption A, for any column γj of Γ (j = 1, . . . , k), there exists a
column of Γ̂candi that is consistent to γj as n → ∞. Explicitly, let el ∈ Rp
denote a p-dimensional vector with the l-th entry one and rest zero, then,
there exists l(j) ∈ {1, . . . , p}, such that
|〈γj, Γ̂candiel(j)〉|
P−→ 1.
2. Under Assumption B, for any column γj of Γ (j = 1, . . . , k), there exists a
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column of Γ̂candi that is consistent to γj as T →∞.
Theorem 4 implies that, by properly ordering the columns of Γ̂candi, we can
achieve that the j-th column of Γ̂candi converges in probability to γj for j =
1, . . . , k. To find this ordering, we define a deviation from commonality metric
for each column of Γ̂candi:














where γ̂j is the j-th column of Γ̂candi.
For the deviation from commonality metric, we expect it to be small if γ̂jγ̂>j
is close to a true CPC and large otherwise. For illustration, we assume T is
large enough such that the sample estimates can be replaced by their pop-
ulation targets; that is, γ̂jγ̂>j = γj̃γ>j̃ for some j̃ ∈ {1, . . . , k} and Si = Σi.
Then the PCPC model (4.1) implies that γ̂>j Siγ̂l = 0 for l 6= j and hence
Dev ({yit}, Γ̂candi, j) = 0. If γ̂jγ̂>j and γ̂lγ̂>l are not close to any CPC, then
γ̂>j Siγ̂l = γ̂
>
j Ψiγ̂l 6= 0 for some i and hence Dev ({yit}, Γ̂candi, j) > 0. In gen-
eral, on the right-hand side of Equation (4.3), the numerator captures the sum
of the squared (j, l) element in Γ̂>candiSiΓ̂candi and the denominator is a normaliz-
ing term that eliminates the effect of magnitude difference in the eigenvalues.
The following theorem shows that Dev ({yit}, Γ̂candi, j) can be used to order the
columns of Γ̂candi and estimate Γ.
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Theorem 5. For all j ∈ {1, . . . , k}, let γ̂jn be the estimate of γj in Γ̂candi, where
jn = arg maxl∈{1,...,p} |〈γ̂l,γj〉|. Assume the PCPC model (4.1) holds.
1. Under Assumption A, as n→∞, we have




In addition, let Ln = {1, . . . , p} \ {1n, . . . , kn}, then there exists a positive
constant C independent of n, such that, as n→∞,
min
l∈Ln




2. Under Assumption B, as T →∞, we have
Dev ({yit}, Γ̂candi, jn)
a.s.−→ 0 and min
l∈Ln
Dev ({yit}, Γ̂candi, l)
a.s.−→ C̃,
where C̃ is a positive constant independent of T and a.s.−→ denotes conver-
gence almost surely.
Given Theorem 5, in practice, we can rank the columns of Γ̂candi in increas-
ing order of Dev ({yit}, Γ̂candi, j) for j = 1, . . . , p and select the first k columns as
Γ̂. If γ̂j is selected, we call γ̂j a common eigenvector estimate and γ̂jγ̂>j a CPC
estimate.
In Theorem 5, the asymptotic results of n → ∞ and T → ∞ are different,
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which results from the different assumptions made in the two cases. When
n → ∞, the deviation from commonality metric is related to the fourth-order
moment of yit, which yields a positive probability limit for a CPC estimate.
When T → ∞, we have γ̂>j Siγ̂l
a.s.−−→ 0 for l 6= j if and only if γ̂jγ̂>j is a CPC
estimate, making the deviation from commonality metric converge to 0 only
for a CPC estimate. Despite these differences, CPC estimates in both cases
have the least deviation from commonality metric among all columns of Γ̂candi
asymptotically, which is essential for identifying CPC estimates from Γ̂candi.
When n and T are small, some columns of Γ̂ may have a large deviation
from commonality metric and are not “close” to any CPC. This bias, however,
will disappear as n→∞ or T →∞, as guaranteed by Theorems 4 and 5. While
our theorems hold for all k ∈ {0, 1, . . . , p − 2, p}, the convergence rate can be
faster for larger k. Under Assumption A, when k is large, {yit} for different i
share more in common, which reduces the variability of the eigenvectors of S.
Under Assumption B, as k increases, the number of parameters in the PCPC
model (1) decreases, and the effective sample size to estimate each parameter
increases. We leave the study of the convergence rate as a function of p and k
to future research. The estimating procedure is summarized in Algorithm 1.
With the number of CPCs given, we generalize the results of Flury (1987) in
three directions. First, Algorithm 1 can consistently estimate CPCs as n→∞,
a case Flury (1987) did not cover. Second, when T → ∞, Theorems 4 and 5
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Algorithm 1 An algorithm to estimate CPCs in model (4.1) when k is known.
Input: A Data set {yit}, t = 1, . . . , T , i = 1, . . . , n, and k ∈ {1, . . . , p− 2, p}.




it/T for each i.
2. Perform eigendecomposition on S =
∑n
i=1 Si/n and obtain the estimated
eigenvectors denoted as Γ̂candi.
3. Reorder the columns of Γ̂candi such that Dev ({yit}, Γ̂candi, j) is increasing
in j, and let Γ̂ be the first k columns of Γ̂candi.
Output: A p× k orthonormal matrix Γ̂.
relax the Gaussian assumption made by Flury (1987). Third, Theorems 4 and
5 guarantee the identification of the CPCs without making assumptions on the
ranks of CPC-related eigenvalues.
Theorems 1 and 2 allow that p > T when n → ∞. When implementing
Algorithm 1, the only condition is that S is positive definite, which is generally
true if p < nT . However, a large pmay substantially increase the computational
complexity and affect finite-sample accuracy, as discussed in Sections 3.3 and
4, respectively.
4.3.2 The number of CPCs is unknown
Based on the idea of Schott (1999), we use a sequential hypothesis testing
approach to find k. For j = 0, 1, . . . , p− 2, we sequentially perform the following
testings
H0,j : k = j ↔ H1,j : k ≥ j + 1.
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Starting from j = 0, if H0,j is rejected, then we proceed to test H0,j+1; otherwise
we estimate k̂ = j. Before the first test, we order the columns of Γ̂candi such
that Dev ({yit}, Γ̂candi, j) is increasing in j. When testing the j-th hypothesis,
we simulate the distribution of Dev ({yit}, Γ̂candi, j + 1) under H0,j, denoted as
F̂j+1, and reject H0,j if Dev ({yit}, Γ̂candi, j + 1) is smaller than the α-quantile
of F̂j+1. The logic of this rejection rule is that Dev ({yit}, Γ̂candi, j + 1) is small
under H1,j, but the α-quantile of F̂j+1 is generally large, since γ̂j+1 is not a
common eigenvector under the null hypothesis. Adjusting for multiple testing
is unnecessary here, since the family-wise type I error is P(k̂ ≥ k0 + 1|k = k0) =
α, if the truth is k = k0.
Given Γ and {λi1, . . . , λip}ni=1 defined in the PCPC model (4.1), we calcu-
late F̂j+1 by repeating the following steps for m times. In practice, we can
approximate Γ using Γ̂ output in Algorithm 1, estimate {λi1, . . . , λij} by diag-
onal entries of Γ̂SiΓ̂ and estimate {λi(j+1), . . . , λip} by the non-zero eigenvalues
of Si − Γ̂ diag{λi1, . . . , λij}Γ̂>. We emphasize that, different from Algorithm 1,
where p can be larger than T , the above approximations are valid when p ≤ T .
1. For each i = 1, . . . , n, independently and uniformly generate R(sim)i from









2. Construct Σ(sim)i = (Γ,R
(sim)
i ) diag{λi1, . . . , λip}(Γ,R
(sim)
i )
>. Generate y(sim)it ,
t = 1, . . . , T , from multivariate Gaussian distribution with mean 0 and
covariance Σ(sim)i .
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3. Given the data set {y(sim)it }, calculate Γ̂
(sim)
candi as described in Algorithm 1
and output Dev ({y(sim)it }, Γ̂
(sim)
candi, j + 1).
Then F̂j+1 =
∑m




candi, j + 1)
output by the l-th simulation. The following theorem shows that the type I er-
ror rate for each test is bounded by α under regularity assumptions.
Theorem 6. Assume the PCPC model (4.1) holds, {yit|Σi} follows a multivari-
ate Gaussian distribution with mean 0 and covariance Σi, and Ri follows a
uniform distribution on its sample space defined in Section 4.2. Then un-
der H0,j, as m → ∞, F̂j+1 converges in distribution to the true distribution of
Dev ({yit}, Γ̂candi, j + 1) given Γ and {λi1, . . . , λip}, i = 1, . . . , n.
A key assumption in Theorem 3 is that data are Gaussian distributed.
When this assumption does not hold, the sequential testing procedure tends
to be conservative, i.e. k̂ < k, since the F̂j+1 is likely to underestimate the
mean and deviation of the distribution of Dev ({yit}, Γ̂candi, j + 1). In practice,
an ad hoc solution is to let k̂ be the smallest j such that Em[F̂j] −
√
V arm(F̂j)
is smaller than Dev ({yit}, Γ̂candi, j), where Em and V arm represent sample av-
erage and variance respectively. This solution shares the central idea of gap
statistics in Tibshirani et al. (2001), which is used to determine the number of
clusters in clustering. The procedure of finding k and estimating Γ is described
in Algorithm 2.
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Another method to find k is to use the hierarchy of partial chi-squared
statistics proposed by Flury (1987, 1988). A nice summary of these statistics
can be found in Pepler et al. (2016). The relevant application of this hierar-
chy in PCPCA is testing k = k1 ↔ k = k2. However, this approach has two
limitations. First, a set of common eigenvector estimates must be prespecified
to implement the test, which is unknown under our setting since CPCs can
rank differently among matrices. Second, the chi-squared test is valid only as
T → ∞, which is a case where our approach also applies. Hence, we do not
consider this method to find k in the simulation studies and data application.
4.3.3 Computational complexity
Given parameters k,m, n, T and p, the computational complexity isO{np2(p+
T )} for Algorithm 1 and O{4k̂mnp2(p + T )} for Algorithm 2, where k̂ is the es-
timate of k by Algorithm 2. It is straightforward to see that the dimension of
matrices p drives the computational complexity at a rate of p3, if T is not too
large. Furthermore, finding k can dramatically increase the run time if k and
m are large.
As a benchmark for actual run time, we set k = p = 20,m = n = T = 100
and ran both algorithms on an Intel I5-8259U 2.3GHz processor in R software
for 10 times. On average, Algorithm 1 took 0.04 seconds and Algorithm 2 took
453.01 seconds, where the difference is the run time due to the iterations for
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Algorithm 2 A two-step algorithm to estimate CPCs in model (4.1) when k is
unknown.
Input: A Data set {yit}, t = 1, . . . , T , i = 1, . . . , n.
Step 1: Get candidates Γ̂candi for Γ.




it/T for each i.
2. Perform eigendecomposition on S =
∑n
i=1 Si/n and obtain the estimated
eigenvectors Γ̂candi.
3. Reorder the columns of Γ̂candi such that Dev ({yit}, Γ̂candi, j) is increasing
in j.
Step 2: Identify Γ̂ from Γ̂candi.
1. Initialize k̂ = 0.
2. Test the hypothesis H0,k̂ : k = k̂ ↔ H1,k̂ : k ≥ k̂ + 1 by a simulation
test described in Section 4.3.2 with significance level α = 0.05 and 1,000
simulations.
3. Based on the testing result: if H0,k̂ is not rejected, return k̂ and Γ̂ as the
first k̂ columns of Γ̂candi; if k̂ = p− 2 and H0,k̂ is rejected, return k̂ = p and
Γ̂ = Γ̂candi; otherwise, increase k̂ by 1 and repeat Step 2 (2).
Output: k̂ ∈ {0, 1, . . . , p− 2, p} and a p× k̂ orthonormal matrix Γ̂.
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estimating k. In comparison, Flury’s algorithm (Flury and Gautschi, 1986) for
CPCA, which assumes k is known, took 5.23 seconds under the same setting,
which is roughly 100 times slower than Algorithm 1. In practice, one could
reduce the run time of Algorithm 2 by parallel programming and improving
code efficiency.
4.4 Simulation study
In this section, we perform three simulation studies. The first confirms the
asymptotic results given by Theorem 5. The second tests the performance of
Algorithms 1 and 2 under various settings. The last compares our proposed
method with existing approaches under different scenarios.
4.4.1 Design and data generating mechanism
In the first simulation, we let p = 20 and k = 10. Define λj = e0.5(p−j) for
j = 1, . . . , p, and assume that {yit} follows a multivariate Gaussian distribu-
tion and CPCs rank randomly in each covariance matrix. For the study of the
asymptotics as n → ∞, we set T = 50 and n = 50, 100, 500, 1000; and for the
study of the asymptotics as T →∞, we set n = 50 and T = 50, 100, 500, 1000. For
each combination of n and T , we simulate data and compare the distribution of
the k-th smallest deviation from commonality metric, which is the largest met-
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ric of CPC estimates, with the distribution of the (k + 1)-th smallest deviation
from commonality metric, which is the smallest metric of non-CPC estimates.
The second simulation is the same as the first one, except that we consider
combinations of different settings: (1) n = T = 15, 30, 100, (2) k = 1, 10, 20 and (3)
{yit} follows a multivariate Gaussian distribution versus Gamma distribution.
For each combination, we simulate data for 1000 times, run Algorithm 1 to get
Γ̂, and run Algorithm 2 to get k̂ for each simulated data set. To measure the
performance of Algorithm 1, we define
∑k
j=1 max |γ>j Γ̂|/k as the accuracy metric
of Γ̂. This metric lies in [0, 1] with larger values indicating better accuracy. To
evaluate the sequential testing procedure, we report k̂ and compare it with the
true k.
The last simulation compares our proposed method (with or without k known,
i.e., Algorithm 1 or Algorithm 2) with Flury’s method (Flury, 1987) and the
PVD method (Crainiceanu et al., 2011) through 4 scenarios below. By “Flury’s
method”, we mean first running the algorithm given by Flury and Gautschi
(1986) to estimate Γ̂candi in CPCA and then selecting k columns associated with
the largest eigenvalues of S. Although Flury (1987, 1988) proposed a method to
estimate k in PCPCA, we do not implement it here, because the order of CPCs
is unknown, as discussed in Section 4.3.2. For the PVD, we use the default
setting; that is, first calculating the top k eigenvectors of Si (denoted as Ui)
and then estimating Γ as the top k eigenvectors of U = (U1, . . . ,Un). There
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are other partial information decomposition methods, such as JIVE and CIFE
described in Section 4.2, but they do not have unique CPC estimates, which
makes the comparison with these methods via simulation infeasible.
Scenario 1: {yit} follows a Gaussian distribution with large n and T . CPCs
are associated with the largest eigenvalues in each covariance matrix.
Scenario 2: {yit} follows a Gaussian distribution with large n and T . The
CPC-associated eigenvalues rank randomly in each covariance matrix.
Scenario 3: {yit} follows a Gamma distribution with large n and T . CPCs
are associated with the largest eigenvalues in each covariance matrix.
Scenario 4: {yit} follows a Gaussian distribution with small n and T . CPCs
are associated with the largest eigenvalues in each covariance matrix.
Scenario 1 serves as the reference case, where the underlying assumptions
of all 4 methods are satisfied. Different from Scenario 1, Scenario 2 has ran-
domly ranked CPC-associated eigenvalues, Scenario 3 has Gamma data gener-
ating distribution and Scenario 4 has small sample size. For each of the 4 sce-
narios, we consider two cases: p = 20 with k = 10 and p = 100 with k = 20, which
represent small-scale and large-scale problem, respectively. When p = 20, we
set n = T = 100 for Scenarios 1-3 and n = T = 30 for Scenario 4 and define
λj = e
0.5(p−j) for j = 1, . . . , p. When p = 100, we set n = T = 1000 for Scenarios
1-3 and n = T = 150 for Scenario 4 and define λj = e0.1(p−j) for j = 1, . . . , p.
Similar to simulation 2, we use
∑k
j=1 max |γ>j Γ̂|/k as the accuracy metric of Γ̂.
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For all simulations, if {yit} follows a Gaussian distribution and CPC-associated
eigenvalues rank randomly, we simulate the data as follows for 1000 repli-
cations. Given p, n, T, k and {λj}pj=1, we sample one Γ from the space {Γ :
Γ>Γ = Ik} as the common eigenvectors, and randomly partition {λj}pj=1 into
two parts: one with k elements as the eigenvalues corresponding to common
eigenvectors (denoted as {λ∗j}kj=1) and the other one consisting of p − k el-
ements (denoted as {λ∗j}
p
j=k+1). For i = 1, . . . , n, we independently sample
λij from a chi-squared distribution with degrees of freedom λ∗j and construct
Ψi = UiDiU
>
i , where Ui is an independent sample from the space {U : U>U =
In−k,U
>Γ = 0(n−k)×k} and Di = diag{λi(k+1), . . . , λip}. Then we construct Σi =
Γ diag{λi1, . . . , λik}Γ> + Ψi and {yit, t = 1, . . . , T} are independently sampled
from N (0,Σi). If {yit} are not Gaussian distributed, we modify the above pro-
cedure by letting yit = Σ
− 1
2
i ỹit, where {ỹit, t = 1, . . . , T} are independently sam-
pled from a multivariate-Gamma distribution with mean 0, variance Ip and
skewness 10Ip. If CPC-associated eigenvalues are the largest k eigenvalues




Simulation results are summarized in Figure 4.2 and Tables 4.1 and 4.2 for
simulations 1, 2 and 3 respectively.
Figure 4.2 shows that the deviation from commonality metric converges to
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its limit when T is fixed and n → ∞, and when n is fixed and T → ∞. This
confirms the results of Theorem 5 and indicates that this metric can be used to
distinguish CPC estimates and non-CPC estimates when either n or T is large.
Table 4.1 displays the performance of Algorithms 1 and 2 under the differ-
ent simulation settings. When data are Gaussian distributed, both algorithms
have high accuracy whenever k, n, T are small, medium or large. As n and T
increases, the performance of both algorithms improves. When the sample size
is small, Algorithm 1 still has a high accuracy in estimating Γ, even under
the non-Gaussian distribution setting. In particular, when n = T = 15 < p,
Algorithm 1 remains valid and has good accuracy, which demonstrates an ad-
vantage with small data. Since implementing Algorithm 2 requires p ≤ T , k̂ is
not estimated when n = T = 15. As k increases, the accuracy of Algorithm 1
slightly increases, which confirms our discussion in Section 4.3.1. Under the
Gamma data generating distribution, the algorithm to find k likely underesti-
mates k when k is large. The reason for this is twofold. First, this algorithm
is conservative for non-Gaussian data (as discussed in Section 4.3.2); second,
when k is large, the number of null hypotheses to reject is large, which reduces
the overall power. As a result, we recommend using Algorithm 2 for Gaussian
distributed data. If k is large, one may not find all CPCs, but the identified
ones are accurate.
Table 4.2 gives the comparison of our proposed method with k known or un-
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known to Flury’s method and PVD. In the first scenario, all methods perform
well, as expected. In the other scenarios, our proposed method performs as
good as or better than Flury’s method and PVD, even when the true number
of CPCs is unknown. In Scenario 2, since both Flury’s method and PVD as-
sume CPCs are associated with the largest eigenvalues for each matrix, their
accuracy is much lower than our proposed method. In Scenario 3, all four meth-
ods have modest accuracy, but our proposed method with k unknown, Flury’s
method and PVD have lower accuracy due to the non-Gaussian distribution.
In contrast, our proposed method with k known remains highly accurate, since
it is semiparametric. In Scenario 4, the size of data is limited compared to the
dimension of matrices, resulting in small accuracy drops of all methods. How-
ever, our proposed method still has the least accuracy drop among all methods.
In all scenarios, our proposed method outperforms Flury’s method and PVD,
even when the true number of CPCs is unknown.
Table 4.1: The accuracy of Algorithm 1 and the sequential testing procedure
under different settings with p = 20.
Average accuracy of Γ̂ Average k̂
Distribution k = 1 k = 10 k = 20 k = 1 k = 10 k = 20
n = T = 15
Gaussian 0.81 0.91 0.93 - - -
Gamma 0.67 0.71 0.83 - - -
n = T = 30
Gaussian 0.95 0.97 0.95 1.20 9.68 18.92
Gamma 0.70 0.86 0.92 0.65 4.04 4.02
n = T = 100
Gaussian 0.98 0.99 0.95 1.26 10.02 20.00
Gamma 0.96 0.98 0.95 1.01 9.50 13.73
96
CHAPTER 4. SEMIPARAMETRIC PCPCA FOR COVARIANCE MATRICES
Figure 4.2: Distribution of the “Deviation from commonality” metric (4.3) as
n (left panel) or T (right panel) goes to infinity for the last CPC estimate and
the first non-CPC estimate. The solid line is the probability limit for the CPC
estimate and the dashed line is the probability limit for the non-CPC estimate
calculated from Theorem 5. The left panel demonstrates that the metric con-
verges in probability to its limit, while the right panel shows that the metric
converges almost surely.
Table 4.2: The accuracy of methods in estimating CPC under different scenar-
ios. Semi-1: the proposed semiparametric method with k known. Semi-2: the
proposed semiparametric method with k unknown. Flury: the Flury’s method.
PVD: population value decomposition.
Semi-1 Semi-2 Flury PVD
Scenario 1 p = 20 1.00 1.00 1.00 0.99
p = 100 1.00 1.00 1.00 0.99
Scenario 2 p = 20 0.99 0.96 0.26 0.50
p = 100 0.99 0.93 0.24 0.20
Scenario 3 p = 20 0.98 0.95 0.88 0.94
p = 100 1.00 0.95 0.91 0.95
Scenario 4 p = 20 0.99 0.99 0.99 0.95
p = 100 0.99 0.99 0.97 0.96
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4.5 Task fMRI data example
We apply the proposed semiparametric PCPC method to the Human Con-
nectome Project (HCP) motor-task fMRI data. The HCP project studies the
brain connectome, both structural and functional, of healthy adults. The data
set includes n = 136 healthy young adults from the most recent S1200 re-
lease. Adapted from the experimental design in Buckner et al. (2011) and
Thomas Yeo et al. (2011), the task fMRI consists of ten task blocks includ-
ing two tongue movement blocks, four hand movement blocks (two left and
two right) and four foot movement blocks (two left and two right), as well as
three 15-second fixation blocks. In each movement task block, a three-second
visual cue was first presented followed by a 12-second movement. Partici-
pants were instructed to follow the visual cue to either move their tongue,
or tap their left/right fingers, or squeeze their left/right toes to map the cor-
responding motor areas. The tasks were randomly intermixed. Once the or-
dering was fixed, the task onsets are nearly consistent across participants. We
used the fMRI data collected and minimally pre-processed by the Washington
University-University of Minnesota HCP Consortium (Van Essen et al., 2012).
The HCP pre-processing steps include distortion correction, image alignment,
volume segmentation, Montreal Neurological Institute (MNI) space registra-
tion, and creating various masks and maps for analysis, and these steps were
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described in detail in Glasser et al. (2013). Given the pre-processed data, we
extracted the time courses (T = 284 time points and repetition time = 0.72
seconds) from 264 brain regions (Power et al., 2011), which are averaged sig-
nals over voxels within the 5 mm radius ball from the region center. Motion
correction was conducted to remove the effect due to head movement during
the scan by regressing on the 12 motion parameters and taking the residuals
as the motion-corrected data (Lindquist et al., 2008). Furthermore, we fit an
ARMA(1,1) model (Lindquist et al., 2008) for each brain region to remove tem-
poral correlation. A figure showing the average of the inter-subject and region
estimated autocorrelation function before and after removing temporal corre-
lation is given in the Supporting Information. This plot suggests that auto-
correaltions were mitigated by ARMA(1,1) filtering. Since Flury’s method and
PVD are not able to identify the CPCs associated with small eigenvalues and
require prespecified k, we present the result from the proposed semiparametric
method only. Results of Flury’s method and PVD letting k = p are given in the
Supporting Information, which differ from the results of the semiparametric
method.
We first focused on functional brain regions in the sensorimotor network
(Power et al., 2011) with p = 35, which is directly related to the task design.
According to the Doornik-Hansen test for multivariate normality by Doornik
and Hansen (2008), there is no sufficient evidence to reject the null hypoth-
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esis that data are normally distributed (p-value 0.12). Among 35 CPC candi-
dates, Algorithm 2 identified 30 as CPCs, which explain 80% of the total vari-
ance of the average covariance matrix. Figure 1 in the Supporting Information
summarises the results of sequential testings. To explore the relationship be-
tween the identified CPCs and the motor tasks, we plotted the average time




j yit/n for j = 1, . . . , 30) and compared
it with task time bins. We also visualized brain regions with loading magni-
tude greater than 0.15 in a brain map. As a result, at least ten of the identified
CPCs are related to tasks (no statistical test is performed) and a list of identi-
fied brain networks is provided in Table 4.3. Figure 4.3(A) presents an example
of task-related CPC (CPC 18). In Figure 4.3(A), the average time course sug-
gests a brain network of right hand movement and left foot movement, which
is confirmed by the brain map. In this component, brain areas associated with
motor control of the right hand yield high negative loadings (blue regions on the
left hemisphere of the brain in Figure 4.3(A)); and regions associated with mo-
tor control of the left foot yield high positive loadings (red regions on the right
hemisphere of the brain in Figure 4.3(A)). The lateral separation of the brain in
terms of the loading sign suggests that during these motor tasks, the associated
left and right hemispheres are functionally negatively correlated. Figure 4.3(B)
presents an example of the CPC that is not related to the tasks. Even though
the time course does not show a clear pattern, this CPC is concentrated in a
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region of the brain, which is modularized as a tongue region by Power et al.
(2011). For the five components that are not identified as CPCs, two appear
task-related and three do not. Since Algorithm 2 can be conservative when the
true number of CPCs is large and the distribution is non-Gaussian based on
simulation, some of these five CPC candidates may be CPCs. For all 35 CPC
candidates, the average time course and the brain maps are provided in the
Supporting Information.
Besides the analysis of the sensorimotor network, we ran Algorithm 2 on all
brain regions (p = 264) and the Doornik-Hansen test shows that it is marginally
significant for the null hypothesis that the whole-brain data are normally dis-
tributed (p-value 0.47). 190 CPC estimates were identified, which explain 50%
of the total variance of the average covariance matrix. Among the 190 CPC
estimates, 66 are associated with the default mode network, 15 are associated
with the visual network, 12 are associated with the sensorimotor network and,
5 are associated with the frontoparietal network. Here we classify a CPC es-
timate as associated with a brain network if, among the regions with loadings
greater than 0.1 in this CPC estimate, at least 25% come from the correspond-
ing network. To compare the results from the sensorimotor-network analysis
and whole-brain analysis, we extracted loadings corresponding to the sensori-
motor network for each common eigenvector estimate in the whole-brain anal-
ysis. Among 30 CPC estimates of sensorimotor-network analysis, 12 are highly
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correlated (absolute value of inner product larger than 0.7) with some CPC can-
didates of whole-brain analysis, suggesting that the brain networks encoded by
these CPCs retain when taking into account regions outside of the sensorimo-
tor network.
Table 4.3: Task-related brain networks identified by Algorithm 2.
CPC No. Variance explained Brain network
3 2.0% Hands, feet
4 2.2% Feet
5 2.1% Right hand
10 2.3% Right foot
11 2.7% Feet
15 2.0% Hands
16 2.2% Left hand
18 2.1% Right hand, left foot
23 1.8% Tongue, feet
24 2.1% Hands, feet
4.6 Discussion
In this paper, we propose a semiparametric PCPC model and provide algo-
rithms to identify CPCs with or without knowing the true number of CPCs.
Furthermore, we prove the asymptotic consistency of our proposed estimators,
even when the data generating distribution is non-Gaussian. In simulation
studies, our estimator consistently outperforms Flury’s method and PVD and
shows high accuracy if the number of CPCs is known. Applied to fMRI data,
our method identifies meaningful brain networks that match the current find-
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Figure 4.3: Average time course (left panel) and brain regions (right panel)
of CPC 18 (upper panel) and CPC 9 (lower panel). In the left panel, each bin
represents the time period of a task. In the right panel, each node is a brain
region, with size standing for the absolute loading and color representing the
sign of the loading (blue for negative and red for positive). Brain regions with
absolute loading smaller than 0.1 are not shown in the figure.
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ings.
In PCPCA, a CPC may not be associated with the largest eigenvalues across
all covariance matrices. For this reason, our proposed method allows for an
arbitrary association between CPC and eigenvalues, which makes the model
more flexible. One challenge resulting from this flexibility is to find k, the
number of CPCs, since the signal of CPCs can be weak or inseparable from non-
common principal components. Our proposed algorithm for finding k performs
well under Gaussian distribution, but can be conservative if the underlying
distribution is non-Gaussian or k is large. Furthermore, sequential hypothe-
sis testing usually requires huge computational resources and can be slow for
high-dimensional matrices. Hence, an efficient and robust method for finding
k will be one future direction.
Our proposed method, as well as the literature, assumes p, the dimension
of covariance matrices, is fixed. One exciting future direction could be finding




For randomized clinical trials using stratified or biased-coin randomization
and having time-to-event outcomes, an open question is how to derive the
asymptotic distribution of covariate-adjusted estimators, such as estimators
of Zhang (2015) and Lu and Tsiatis (2011) for survival functions. Our conjec-
ture is that results of Chapter 3 can be generalized to handle this question
and stratified randomization will lead to a variance reduction with the same
formula (3.9) as the K-M estimator.
When identifying shared eigenvectors, our proposed estimator in Chapter 4
assumes that each observed data vector is independent of each other. In brain
imaging, however, there is auto-correlation among different brain scans of the
same subject. In our data example presented in Section 4.5, we use a time
series model to remove such correlation, but how to best handle dependency of
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Supporting Information, available at https://doi.org/10.1111/biom.
13062, includes the following: (a) definitions of the sample variance and co-
variance used in Section 2.4.2; (b) simulations to generate visualizations of the
relationship among the imbalance, unadjusted estimator, and ANCOVA esti-
mator; (c) proofs of theoretical results; (d) relationship among different types
of R-squared; (e) data analyses accounting for missing data; (f) link to the code





Supplementary Material, available at https://arxiv.org/abs/1910.
13954, includes the following: (a) regularity conditions to Theorem 2; (b) con-
sistent estimators of the asymptotic variance V defined in Theorem 2; (c) asymp-
totic variance V (a)(t, t′), which is described in Theorem 3, and a consistent esti-
mator for V (a)(t, t); (d) proofs of Theorem 1, Corollary 1 and Theorem 2 and (e)






Proofs of Theorems 4, 5, 6, and additional results of data application refer-
enced in Section 3.7 are available with this paper at the Biometrics website on
Wiley Online Library https://doi.org/10.1111/biom.13369. The R code
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